

Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure consequent to COPD

CAG-00465N

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Decision Summary

This final NCD provides coverage of RADs for the treatment of chronic respiratory failure that often accompanies COPD. In addition, for the first time, Medicare establishes coverage criteria for HMV for patients with COPD. For all other patient indications not included within the NCD, the MACs have authority to decide coverage.

Decision Memo

DECISION SUMMARY

This final NCD provides coverage of RADs for the treatment of chronic respiratory failure that often accompanies COPD. In addition, for the first time, Medicare establishes coverage criteria for HMV for patients with COPD. For all other patient indications not included within the NCD, the MACs have authority to decide coverage.

TO: Administrative File: CAG-00465N

SUBJECT: National Coverage Determination for Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chronic Obstructive Pulmonary Disease (COPD)

DATE: June 9, 2025

I. Decision

A. General

Respiratory assist devices (RADs) with bi-level capability, with or without a backup rate feature, are devices that typically use a non-invasive interface (mask) to deliver a higher level of airway pressure when the patient inhales than when the patient exhales. A backup rate feature on certain RADs enables the device to provide a prespecified respiratory rate if the patient's spontaneous respiratory rate decreases below a set number.

Compared with RADs, home mechanical ventilators typically have additional ventilatory modes, monitoring, ventilator control, and safety, alarm, and backup power features (batteries).

B. Nationally Covered Indications

I. Respiratory Assist Devices (RADs)

(a) Initial Coverage Criteria

(i) RAD with Backup Rate Feature

The Centers for Medicare & Medicaid Services (CMS) will cover in the home a RAD with backup rate feature to deliver high intensity noninvasive ventilation (NIV) as treatment for patients with chronic respiratory failure (CRF) consequent to chronic obstructive pulmonary disease (COPD). A RAD with backup rate feature is covered in the home for an initial 6-month period for patients with COPD when **all the following** criteria are met:

- The patient exhibits hypercapnia as demonstrated by $\text{PaCO}_2 \geq 52$ mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO_2 ; **and**
- Sleep apnea is not the predominant cause of hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of hypercapnia.); **and**
- The patient demonstrates **one of the following** characteristics:
 - Stable COPD, without increase in or new onset of more than one respiratory symptom (cough, sputum production, sputum purulence, wheezing, or dyspnea) lasting 2 or more days and no change of pharmacological treatment during the 2-week period before initiation of NIV, **or**
 - Hypercapnia present for at least 2 weeks post hospitalization after resolution of an exacerbation of COPD requiring acute NIV.

By the end of the initial 6-month period, a RAD with backup rate feature must be utilized as high intensity therapy, defined as a minimum IPAP ≥ 15 cm H₂O and backup respiratory rate of at least 14 breaths per minute.

(ii) RAD without Backup Rate Feature

CMS will cover in the home a RAD without backup rate feature for a patient with CRF consequent to COPD who cannot tolerate high intensity NIV **or** for whom the backup rate feature is otherwise medically inappropriate. A RAD without backup rate feature is covered in the home for an initial 6-month period for patients with COPD when **all of the following** criteria are met:

- The patient exhibits hypercapnia as demonstrated by $\text{PaCO}_2 \geq 52$ mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO_2 ; **and**
- Sleep apnea is not the predominant cause of the hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of the hypercapnia.).

(iii) RAD Upon Hospital Discharge

CMS will cover in the home a RAD with or without backup rate feature immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient required either a RAD or ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO_2 after discharge.

(b) Continuing Usage Criteria for a RAD

Patients must be evaluated at least twice within the first year after initially receiving a RAD. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.

First evaluation:

By 6 months after receiving initial coverage of a RAD, the treating clinician must establish that usage criteria and clinical outcomes are being met. Specifically, the patient must be determined by a clinician to use the RAD at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period and achieve **at least one** the following clinical outcomes:

- Normalization (< 46 mmHg) of PaCO_2 , **or**
- Stabilization of a rising PaCO_2 , **or**
- 20% reduction in PaCO_2 from baseline value, **or**
- Improvement of **at least one** of the following patient symptoms associated with chronic hypercapnia:
 - headache
 - fatigue
 - shortness of breath
 - confusion
 - sleep quality

Second evaluation:

Between 7-12 months after initially receiving a RAD, the treating clinician must establish the patient is using the device at least 4 hours per 24-hour period on at least 70% of days in each paid rental month.

Post second evaluation:

The patient must be using the device at least 4 hours per 24-hour period on at least 70% of days in each remaining paid rental month and any month in which accessories/supplies are dispensed.

II. Home Mechanical Ventilators

(a) Initial Coverage Criteria

CMS will cover a home mechanical ventilator (HMV) used in a volume targeted mode as treatment for a patient with chronic respiratory failure (CRF) consequent to chronic obstructive pulmonary disease (COPD) who exhibits certain clinical characteristics.

*(i) An HMV is covered for an initial 6-month period for patients with COPD when **all of the following** criteria are met:*

- The patient exhibits hypercapnia as demonstrated by $\text{PaCO}_2 \geq 52$ mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO_2 ; **and**
- Sleep apnea is not the predominant cause of the hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of the hypercapnia.); **and**
- The patient demonstrates **at least one** of the following characteristics:
 - Requires oxygen therapy at an $\text{FiO}_2 \geq 36\%$ or $\geq 4\text{L}$ nasally, **or**
 - Requires ventilatory support for more than 8 hours per 24-hour period, **or**
 - Requires the alarms and internal battery of an HMV, because the patient is unable to effectively breathe on their own for more than a few hours and the unrecognized interruption of ventilatory support is likely to cause a life-threatening condition if the patient or caregiver cannot be otherwise alerted as determined by the treating clinician, **or**
 - Per the treating clinician, none of the below are likely to be achieved with consistent use of a RAD with backup rate feature for at least 4 hours per 24-hour period on at least 70% of days because the patient's needs exceed the capabilities of a RAD as justified by the patient's medical condition:
 - Normalization (< 46 mmHg) of PaCO_2 , **or**
 - Stabilization of a rising PaCO_2 , **or**
 - 20% reduction in PaCO_2 from baseline value, **or**
 - Improvement of **at least one** of the following patient symptoms associated with chronic hypercapnia:
 - headache
 - fatigue
 - shortness of breath
 - confusion
 - sleep quality

(ii) Home Mechanical Ventilator Use Upon Hospital Discharge

CMS will cover in the home an HMV used in a volume targeted mode immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient's needs exceeded the capabilities of a RAD (with or without backup rate feature) and required usage of a ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO₂ after discharge.

(b) Continuing Usage Criteria for an HMV

Patients must be evaluated at least twice within the first year after initially receiving an HMV. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.

First evaluation:

By 6 months after receiving initial coverage of an HMV, the treating clinician must establish that usage criteria are being met. The patient must be determined by a clinician to use the HMV at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period.

Second evaluation:

Between 7-12 months after initially receiving an HMV, the treating clinician must establish the patient is using the device at least 4 hours per 24-hour period on at least 70% of days in each paid rental month.

Post second evaluation:

The patient must be using the device at least 4 hours per 24-hour period on 70% of days in each paid rental month.

(c) Masks for HMVs

For patients who use an HMV in a volume targeted mode: 1) for greater than 8 hours in any 24-hour period; and 2) use an oronasal mask at night, a different interface (e.g., mouthpiece ventilation or nasal mask) is covered for daytime hours. Note, coverage of such supplies does not exclude coverage of additional supplies necessary for the effective use of the HMV.

C. Nationally Non-Covered Indications

N/A

D. Other

Medicare Administrative Contractors (MACs) may make reasonable and necessary determinations under section 1862(a)(1)(A) of the Social Security Act for any patient seeking initial coverage or continued coverage for RADs or HMVs used as treatment of chronic respiratory failure consequent to COPD.

See Appendix A for the manual language.

Additionally, we will make conforming changes in Section 280.1 (Durable Medical Equipment List) of the National Coverage Determinations (NCD) Manual to add a cross reference to the new NCD Section 240.9 (NIPPV in the Home for the Treatment of CRF Consequent to COPD).

II. Background

Throughout this document we use numerous acronyms, some of which are not defined as they are presented in direct quotations. Please find below a list of these acronyms and corresponding full terminology:

ABG - arterial blood gas
 AECOPD - acute exacerbation of COPD
 ATS - American Thoracic Society
 CMS - Centers for Medicare & Medicaid Services
 CO₂ - carbon dioxide
 COPD - Chronic obstructive pulmonary disease
 CRF - chronic respiratory failure
 DME - durable medical equipment
 DME MAC - Durable Medical Equipment Medicare Administrative Contractor
 DMERC - Durable Medical Equipment Regional Carrier
 EPAP - expiratory positive airway pressure
 ERS- European Respiratory Society
 FDA - Food and Drug Administration
 FEV₁ - forced expiratory volume in 1 second
 FVC - forced vital capacity
 GOLD - Global Initiative for Chronic Obstructive Lung Disease
 GRADE - Grading of Recommendations, Assessment, Development and Evaluation
 HMV - home mechanical ventilator
 HRQoL - health related quality of life
 IPAP - inspiratory positive airway pressure
 ISO - International Organization of Standardization
 LCD - Local Coverage Determination
 LTH-NIV - long term home noninvasive ventilation
 LTOT - long term oxygen therapy
 NCA - National Coverage Analysis
 NCD - National Coverage Determination
 NIPPV - noninvasive positive pressure ventilation (also known as NPPV)

NIV - noninvasive ventilation

O₂ - oxygen

PaO₂ - partial pressure of O₂ in the arterial blood

PaCO₂ - partial pressure of CO₂ in the arterial blood

PICO - patients, intervention, comparator, outcome

RAD - respiratory assist device

RCT - randomized controlled trial

SOE - strength of evidence

US - United States

Chronic Obstructive Pulmonary Disease

The GOLD Report, published by the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD), defines chronic obstructive pulmonary disease (COPD) as... "a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration, and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction" (Agusti et al., 2023). COPD may have a multitude of causes, including genetic abnormalities, abnormal lung development, cigarette smoking, biomass and pollution exposure, lung infections, asthma, or the disease may be of unknown cause (Celli et al., 2022). It is a major cause of disability and is the third leading cause of death in the United States (Macrea & Coleman 3rd, 2022). It has been reported that of the Medicare population with coverage in 2018, 16.5% experienced COPD (Malla, Bodduluri, Sthanam, Sharma & Bhatt, 2023).

Though COPD is a chronic illness, affected individuals can periodically experience acute worsening of symptoms characterized clinically by increased dyspnea, cough, sputum production and sputum purulence. This acute worsening of symptoms has been termed acute exacerbation of COPD (AECOPD). COPD exacerbations are common and can result in lost work productivity, increased utilization of healthcare resources, temporary or permanent reductions in lung function and exercise capacity, hospitalization, and sometimes death (Kim & Aron, 2018). It has been shown that patients who have survived an acute episode of hypercapnic respiratory failure due to an exacerbation of COPD, have a poor prognosis with a high risk for readmission and death within a year (Ankjaergaard et al., 2016). In fact, COPD represents the third most common cause of hospital readmissions among Medicare beneficiaries (Coleman, Wolfe & Kalhan, 2019). Approximately 20% of Medicare beneficiaries hospitalized for acute exacerbations of COPD are readmitted within 30 days of discharge (Bhatt, Wells, Iyer et al., 2017).

Respiratory Failure

The respiratory system is responsible for the uptake of oxygen (O₂) and the removal of carbon dioxide (CO₂) from the body (Windisch, Geiseler, Simon, Waltersbacher & Dreher, 2018). Respiratory insufficiency and subsequent failure are caused by impairment of gas exchange between the ambient air and the circulating blood and occurs when the pulmonary system cannot maintain a steady state of gas exchange in response to the metabolic demands of the body, resulting in the inadequate delivery of O₂ and/or inadequate elimination of CO₂ (Dekerlegand, Cahalin & Perme, et al., 2007).

The respiratory system consists of two parts: the lungs for gas exchange and a pump (the chest wall, respiratory muscles and the nervous system that controls the muscles) to ventilate or move air into/out of the lungs. In general, if there is failure of the gas exchange system, hypoxemia (low blood oxygen) results; failure of the "pump" leads to hypoventilation (which also causes hypoxemia) and hypercapnia (high levels of CO₂ in the blood). Hypercapnia is the hallmark of ventilatory failure (Roussos & Macklem, 1982).

The ventilatory pump controls the volume of air moving in/out of the airways and the rate at which the air moves. Common measures used to evaluate airway function are forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁). FVC is the volume of air forcibly exhaled from maximal inspiration to maximal exhalation. FEV₁ is the volume of air moved during the first second of the FVC maneuver and represents the air movement through the larger airways of the lungs (Dekerlegand et al., 2007). Spirometry is used to assess these measures and is needed to establish the diagnosis of COPD. Specifically, a forced vital capacity maneuver during spirometry showing the presence of a post-bronchodilator FEV₁/FVC ratio < 0.7 is required for the diagnosis of COPD. Use of the ratio FEV₁/FVC is not foolproof; yet in the appropriate context of symptoms and history of risk factors, the risk of misdiagnosis is limited. The FEV₁ also serves to determine the severity of airflow obstruction (mild, moderate, severe, and very severe) (Agusti et al., 2023).

Arterial blood gases (ABGs) can also be used to examine the performance of the respiratory system. ABGs are measures of the partial pressure of O₂ (PaO₂), partial pressure of CO₂ (PaCO₂), levels of bicarbonate (HCO₃) and the pH of the arterial blood. These factors are key to understanding the balance between the respiration (gas exchange between the alveolar air spaces and the blood) and ventilation processes. Hypoventilation (inadequate ventilation) causes PaCO₂ to increase. This increase in PaCO₂ will cause the blood pH to fall as it becomes more acidic (Dekerlegand et al., 2007).

COPD and Chronic Respiratory Failure with Hypercapnia

Chronic hypercapnia respiratory failure is common in severe COPD. Its prevalence ranges from 23%-38% (Macrea & Coleman, 2022). Patients with end-stage chronic hypercapnia secondary to COPD may experience fatigue, (morning) headache, loss of energy and dyspnea leading to impaired health-related quality of life (HRQoL) (van der Leest & Duiverman, 2019). They are also prone to repeated hospitalization with rapid clinical deterioration (Kaminska et al., 2021; Marwah, Dhar, Choudhary & Elliot, 2022). Moreover, compared to normocapnic patients, those who experience chronic hypercapnia from COPD have higher mortality rates (Daher & Dreher, 2020).

Noninvasive Positive Pressure Ventilation (NIPPV)

Non-invasive ventilation (NIV) is the application of ventilatory support through a non-invasive interface, usually a nasal or oronasal mask (Raveling, Vonk & Struik, et al. 2021). Currently the most frequently used form of NIV is positive pressure ventilation (Csoma, Vulpi & Dragonieri, et al., 2022), a treatment strategy that is often attempted to correct the respiratory impairments in COPD. NIV can be delivered in-facility or more chronically, at home. Though home therapy is generally applied at night (Rabec, Rodenstein, Leger et al., 2011), in patients with COPD the resultant blood gas changes can extend to the daytime hours (Orr, Azofra & Tobias, 2020).

Ventilation that is applied with positive pressure (higher than atmospheric pressure) pushes air or a mixture of oxygen combined with other gases into the lungs (Home Ventilator Guide, 2017; Potchileev, Doroshenko & Mohammed, 2023). Although the exact mechanism of benefit may not be known, noninvasive positive pressure ventilation (NIPPV) appears to reduce the effort needed to breathe by promoting respiratory muscle rest, enhancing both tidal volumes (the amount of inspired/expired air in each breath) and muscle fiber dynamics and reducing lung hyperinflation. Through these actions the use of NIPPV is thought to lead to improved elimination of carbon dioxide (Hatipoglu & Aboussouan, 2022).

For the administration of NIPPV in general, it is possible to choose from a selection of equipment including continuous positive airway pressure (CPAP) devices, bi-level positive airway pressure (BPAP) devices (known as respiratory assist devices or RADs in Medicare) and home mechanical ventilators (HMs) (Gudivada, Rajasurya & Spector, 2020).

A CPAP device is one that delivers a constant level of positive airway pressure throughout the entire respiratory cycle (inspiration and expiration) (Kelly, Higgins & Chandra, 2015). It is the standard treatment for obstructive sleep apnea (Pavwoski & Shelgikar, 2017). Whereas CPAP is a type of NIPPV, it is not the focus of this NCA. Instead, the majority of this analysis will emphasize bi-level ventilation.

Bi-level positive airway pressure (BPAP) devices provide inspiratory positive airway pressure (IPAP) during inhalation and expiratory positive airway pressure during exhalation (EPAP). The IPAP and EPAP settings can be adjusted separately, with the inspiratory positive airway pressure (IPAP) being the higher level of pressure delivered. The IPAP serves to support and/or augment the tidal volume, while EPAP is set at a lower value in order to maintain upper airway patency and prevent alveolar closure during expiration. The difference between these two values is known as the pressure support. When properly applied, these pressures increase the patient's inspiratory depth and quantity of inhaled air to improve ventilation (Kelly, Higgins & Chandra, 2015; Kelly & Selim, 2023; Macrea & Coleman, 2022).

There are two broad categories of devices that can deliver bi-level NIPPV: respiratory assist devices with bi-level pressure capability (RADs) and non-invasive home mechanical ventilators (HMs). RAD devices are more common; they need to be plugged into the wall and the pressure that can be generated is limited. Compared with RADs, HMs typically have additional ventilatory modes (discussed below), monitoring, ventilator control, and safety, alarm, and backup power features (batteries). These devices are classified as "life support devices" by the Food and Drug Administration (FDA) (Wilson et al., 2019; Wilson, et al. 2020; Macrea & Coleman, 2022; Singh & Cao, 2020; Orr, 2023).

In addition to choosing the appropriate type of equipment for any given patient, it is also important to determine the mode in which the equipment functions in order to provide ventilatory assistance. A ventilation mode is a predefined pattern of interaction between a patient and the ventilation equipment (Chatburn, 2009) and therefore determines how a home respiratory device augments patient respiratory effort (Hansen-Flaschen & Ackrivo, 2023). More simply put perhaps, the mode of ventilation determines whether the ventilator or the patient initiates breathing and whether it is the patient or the device that performs most of the work of breathing (Dekerlegand et al., 2007).

By convention, the most basic designation of a mode is whether it is pressure or volume controlled. Pressure control means that the ventilator attempts to deliver a predetermined pressure output despite respiratory system characteristics of resistance, elastance or inspiratory effort. Volume control means that the ventilator attempts to deliver volume or flow according to a predetermined output, independent of factors that include inspiratory effort or compliance/resistance of the respiratory system. Additionally, the ventilatory mode will characterize the breaths being allowed (spontaneous or mandatory), as well as their timing, manner of initiation and stoppage (Chatburn, 2009).

The simplest bi-level positive airway pressure mode is the spontaneous (S) mode. Inspiratory effort by the patient initiates an assisted breath to the fixed IPAP; there is no backup rate in the event the patient's spontaneous respiratory rate decreases. In contrast to the S mode, the spontaneous/timed (ST) mode guarantees mandatory, timed breaths by the device if the patient's spontaneous respiratory rate decreases below the set backup rate. The purpose of the backup rate feature of the ST mode is to ensure a minimum number of breaths per minute if the patient is unable to do so spontaneously. (Singh & Cao, 2020).

In addition to the bi-level pressure modes discussed above, some RADs can deliver hybrid modes of pressure and volume ventilation (Singh & Cao, 2020). Also, in addition to pressure control ventilation, HMs can also deliver volume controlled and/or volume pre-set ventilation modes (Wilson et al., 2020).

The term NIV (noninvasive ventilation) is at times substituted for the terminology of NIPPV or NPPV (Pierson, 2009). In this NCD/NCA these three terms will be used interchangeably, depending on the preferences of the authors whose work is being described. Because RADs and home mechanical ventilators can both be considered types of non-invasive positive pressure mechanical ventilator devices (Wilson et al., 2019), wherever possible, to avoid confusion in this NCA, each device will be identified purposefully by their specific terminology and/or characteristics.

III. History of Medicare Coverage

In 1998, the National Association for Medical Directors of Respiratory Care (NAMDR) hosted a multi-disciplinary consensus conference to more clearly discern the appropriate indications for NIPPV therapy. During the conference, it was noted that additional research studies and clinical trials were necessary for the selection of appropriate candidates for this therapy and to determine outcomes of noninvasive positive pressure ventilation in patients with COPD. In part based on suggestions put forth by participants of the 1998 conference, the Durable Medical Equipment Medicare Administrative Contractors (DMACs, but then called Durable Medical Equipment Regional Carriers or DMERCs) developed a regional medical review policy for RADs effective October 1, 1999 (CAG-00052, 2001).

For a bi-level respiratory assist device to have been covered under the regional medical review policy at that time for patients with COPD, the treating physician was required to document in the patient's medical record symptoms characteristic of sleep-associated hypoventilation, such as daytime hypersomnolence, excessive fatigue, morning headache, cognitive dysfunction, dyspnea, etc. Additionally, the policy for RADs used for COPD patients required that the patients meet all of the following criteria:

- An arterial blood gas carbon dioxide reading (PaCO₂), done while awake and breathing the patient's usual FiO₂, be \geq 52 mm Hg, and
- Sleep oximetry demonstrating an oxygen saturation \leq 88% for at least five continuous minutes, done while breathing the patient's usual FiO₂, and
- Prior to initiating therapy, obstructive sleep apnea (and treatment with continuous positive airway pressure) had been considered and ruled out.

If all of the above criteria for patients with COPD were met, a RAD without backup rate feature could be covered. For COPD patients who qualified for a RAD without backup rate feature, if at a time no sooner than 61 days after initial issue and compliant use the treating physician believed the patient required a RAD with backup, then this device could be covered if all of the following criteria were met:

- An arterial blood gas PaCO₂, repeated no sooner than 61 days after initiation of compliant use of the RAD without backup rate feature, done while awake and breathing the patient's usual FiO₂, remained ≥ 52 mm Hg;
- A sleep oximetry, repeated no sooner than 61 days after initiation of compliant use of a RAD without backup rate feature, and while breathing with the RAD without backup rate feature, demonstrated an oxygen saturation $\leq 88\%$ for at least five continuous minutes, done while breathing oxygen at 2 LPM or the patient's usual FiO₂ (whichever was higher);
- A signed and dated statement from the treating physician, completed no sooner than 61 days after initiation of the RAD without backup rate feature, declared that the patient has been compliantly using the RAD without backup rate feature (at least an average of 4 hours per 24 hour period) but that the patient was NOT benefiting from its use;
- A Medicare beneficiary statement completed by the patient no sooner than 61 days after initiation of the RAD without backup rate feature documented that specified coverage criteria had been met.

Interested parties expressed concern with this policy, and especially with the prerequisite trial waiting period of NIPPV without backup rate feature before use of a noninvasive ventilation with a backup for COPD patients. In 2001, the NCA decision memorandum for Noninvasive Positive Pressure RADs for COPD (CAG-00052N) examined the clinical evidence for the use of these devices in the cited disease with the expectation of establishing a national coverage policy. Specifically, the question was asked if evidence existed to demonstrate that severely ill COPD patients should have direct placement on a RAD with a backup rate feature without first having a trial of a respiratory assist device without a backup rate feature. Despite a thorough search of the medical literature and review of all literature submitted by requestors, CMS was unable to find any studies directly related to this analytic question and no national coverage decision was issued on this topic. Instead, CMS has maintained MAC discretion for coverage of RADs for qualifying COPD patients (CAG-00052N, 2001; LCD 33800, 2021).

NCD 280.1, Durable Medical Equipment (DME) Reference List, provides for coverage of ventilators for the treatment of neuromuscular diseases, thoracic restrictive diseases, and chronic respiratory failure consequent to chronic obstructive pulmonary disease.

A. Current Request

CMS received a complete, formal request for a reconsideration of §280.1 of the National Coverage Determinations (NCD) Manual, (Pub. 100-03, Chapter 1, Part 4) regarding coverage of positive and negative pressure ventilators as part of the Durable Medical Equipment Reference List. This request was provided by the Optimum Noninvasive Ventilation Medicare Access Promotion Technical Expert Panel (TEP), consisting of representatives from the American College of Chest Physicians, the American Academy of Sleep Medicine, the American Association for Respiratory Care, and the American Thoracic Society. This NCD request is a long-standing request dating back to 2016 and revised in 2021. Based on the original NCD request, CMS held a MEDCAC in 2020. Soon after, the NCD requestors formed a TEP that was designed to address various segments of the respiratory patient population who can benefit from noninvasive ventilation. The panel identified the standards of care related to device selection for specific patient populations and the peer-reviewed literature supporting these approaches to care.

CMS accepted the request for NIPPV in the home for the treatment of chronic respiratory failure (CRF) consequent to COPD and believes the subject matter is best served by development of a new NCD section. Therefore, the scope of this NCA is limited to NIPPV in the home for the treatment of CRF consequent to COPD and no other portion of NCD 280.1 will be evaluated.

The formal request letter can be viewed via the tracking sheet for this NCA on the CMS website at <https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=315&ncacaldoctype=all&status=all&sortBy=status&bc=17>.

B. Benefit Category

Medicare is a defined benefit program. For an item or service to be covered by the Medicare program, it must fall within one of the statutorily defined benefit categories outlined in the Social Security Act. Both RADs and HMs are covered under the Durable Medical Equipment benefit (Social Security Act §1861(s) (6)).

IV. Timeline of Recent Activities

Date	Actions Taken
September 11, 2024	CMS posts a tracking sheet announcing the opening of the NCA. The first 30-day public comment period begins.
October 11, 2024	First public comment period ends. CMS receives 72 comments.
March 11, 2025	CMS posts proposed Decision Memorandum. Second 30-day public comment period begins.
April 10, 2025	Second 30-day public comment period ends. CMS receives 199 timely comments.
June 9, 2025	CMS posts final decision memorandum.

V. Food and Drug Administration (FDA) Status

Section 204 of the Food and Drug Administration Modernization Act of 1997 (Pub. L. 105–115) amended section 514 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360d). Amended section 514 of the FD&C Act allows FDA to recognize consensus standards developed by international and national organizations for use in satisfying portions of device premarket review submissions or other requirements (Federal Register, 2024).

One such consensus standard, ISO 80601-2-79:2024: Medical electrical equipment Part 2-79, applies to the basic safety and essential performance of ventilatory support equipment, such as respiratory assist devices, used in the home environment for those individuals with ventilatory impairment. The

ventilatory support equipment within the scope of this standard is intended for use of patients who have ventilatory impairment, the most fragile of whom would not likely experience injury with the loss of this artificial ventilation. An example of the pertinent patient population for whom these equipment standards would be applicable include those individuals with mild to moderate COPD. The equipment within the scope of this standard is not intended for patients who are dependent on artificial ventilation for their immediate life support and may be operated by non-healthcare personnel.

ISO 80601-2-72:2023, "Medical electrical equipment Part 2-72: Particular requirements for basic safety and essential performance of home healthcare environment ventilators for ventilator-dependent patients," applies to the basic safety and essential performance of a ventilator intended for use in the home environment. This equipment is meant for those individuals who need differing levels of support from artificial ventilation, including patients who are ventilator dependent. This equipment is intended to be operated by non-healthcare personnel with varying degrees of training.

VI. General Methodological Principles

When making national coverage determinations (NCDs), CMS generally evaluates relevant clinical evidence to determine whether or not the evidence is of sufficient quality to support a finding that an item or service falling within a benefit category is reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. The critical appraisal of the evidence enables us to determine to what degree we are confident that: 1) the specific assessment questions can be answered conclusively; and 2) the intervention will improve health outcomes for beneficiaries. An improved health outcome is one of several considerations in determining whether an item or service is reasonable and necessary.

A detailed account of the methodological principles of study design that the Agency utilizes to assess the relevant literature on a therapeutic or diagnostic item or service for specific conditions can be found in the [CMS National Coverage Analysis Evidence Review Guidance Document](#).

Public comments sometimes cite published clinical evidence and give CMS useful information. Public comments that give information on unpublished evidence such as the results of individual practitioners or patients are less rigorous and therefore less useful for making a coverage determination. CMS responds in detail to the public comments on a proposed national coverage determination when issuing the final national coverage determination.

VII. Evidence

A. Introduction

This section provides a summary of the evidence we considered during our review. The evidence reviewed to date includes the published medical literature on noninvasive positive pressure ventilation (NIPPV) for COPD. For this national coverage analysis (NCA), we searched PubMed and Embase for published medical literature in the form of clinical trials, systematic reviews, meta-analyses, evidence-based guidelines and professional society recommendations to answer the evidence questions below.

B. Discussion of Evidence

1. Evidence Question(s)

Question 1: In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to provide coverage of a RAD with backup rate feature for initial NIV support in the home when the individual either exhibits stable COPD or is status post a recent exacerbation of COPD?

Question 2: In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to determine if there are any conditions under which coverage of an HMV is reasonable and necessary?

Question 3: In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to establish a 180-day trial period to determine if the use of home NIPPV delivered either from a bi-level respiratory assist device or an HMV, is reasonable and necessary?

2. External Technology Assessments

Wilson M, Wang Z, Dobler C, Morrow A, Beuschel B, Alsawas M, Benkhadra R, Seisa M, Mittal A, Sanchez M, Daraz L, Holets S, Murad MH. Noninvasive Positive Pressure Ventilation in the Home. Project ID: PULT0717 (Prepared by the Mayo Clinic Evidence-Based Practice Center under Contract No. HHS2902015000131_HHS29032004T).

Rockville, MD: Agency for Healthcare Research and Quality. March 2019.

<http://www.ahrq.gov/clinic/epcix.htm>

This Technology Assessment (TA) was prepared, in part, as reference material for the CMS Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting, held virtually on July 22, 2020 (see Section 4-Medicare Evidence Development & Coverage Advisory Committee below). The purpose of the MEDCAC was to review the evidence specific to the home use of noninvasive positive pressure ventilation by patients with chronic respiratory failure consequent to COPD. The goal of the TA was to evaluate home NIPPV in adult patients with chronic respiratory failure secondary to a variety of diseases affecting the pulmonary system, in terms of initiation, continuation, effectiveness, adverse events, equipment parameters and required respiratory services. Only the results of the TA examining patients with chronic respiratory failure due to COPD are reported below.

The full document can be found at: <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id108TA.pdf>.

The authors searched the National Guideline Clearinghouse, MEDLINE, EMBASE, SCOPUS, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from January 1, 1995 to November 6, 2019. Randomized and comparative nonrandomized studies (prospective and retrospective) that enrolled adults with chronic respiratory failure who used NIPPV for ≥ 1 month at home using an HMV, bi-level positive airway pressure [BPAP] device, or CPAP were evaluated. The outcomes of interest were compared between the NIPPV and usual care or another mode or type of NIV. Outcomes included mortality, hospitalization, need for intubation, quality of life, emergency department visits, intensive care unit admissions/readmissions, COPD exacerbations, activities of daily living, dyspnea, sleep quality, exercise tolerance and adverse events.

The TA did not report any conclusions specifically related to our Evidence Questions above. However, the TA did demonstrate the following for patients with COPD:

- No studies compared the initiation criteria among different devices (HMV vs. BPAP vs. CPAP).
- The criteria used to start NIPPV were variable and included differing laboratory parameters of hypercapnia, hypoxia or a combination of the two.
- No studies directly compared the outcomes of patients based on different criteria of device initiation or compared initiation criteria between different devices (HMV vs. BPAP vs. CPAP).
- Processes used to titrate NIPPV were variable and included targeting reduction in hypercapnia, reduction in hypoxia, and reduction in patient symptoms.
- In patients with stable COPD, BPAP was associated with lower mortality, higher quality activities of daily living and reduced dyspnea.
- In patients with recent exacerbations of COPD, BPAP was associated with the reduced need for intubation.
- HMV (compared individually with BPAP, CPAP or no device) was associated with significantly fewer hospital admissions.
- Mean device usage per day (BPAP and HMV) ranged from 4.5-9.0 hours.

Furthermore, though the evidence was limited, approximately one third of patients who use NIPPV via any device for any studied condition experienced non-serious adverse events such as facial rash, mucosal dryness, mask discomfort, etc. Based on direct comparisons, no significant differences in adverse events between devices or between devices and no device were found. However, the authors noted that the evaluation of adverse events was limited by the fact that most of the included studies did not evaluate adverse events and the majority of the rest did not use a consistent approach for reporting and evaluation.

3. Internal Technology Assessment

To answer our evidence questions, we identified relevant studies in PubMed and EMBASE by using a combination of pertinent search terms including such words as COPD, noninvasive positive pressure ventilation, home/ domiciliary, systematic review and meta-analysis. To ensure that we captured all the relevant articles, a search was conducted independently by the contractor International Consulting Associates (ICA) for the CMS Coverage and Analysis Group (CAG).

We also reviewed references submitted to us by commenters and performed a hand search of retrieved bibliographies to identify other applicable literature for our review.

We originally anticipated that we would evaluate systematic reviews/meta-analyses of randomized controlled and/or observational trials that compared the outcomes of treatment of domiciliary noninvasive ventilation for patients with COPD and hypercapnia with the outcomes of those patients who did not receive NIPPV in the home. However, as will be explained further below, the technique of delivering NIPPV has changed markedly over the last 20+ years. We found that the systematic reviews/meta-analyses pertinent to our evidence questions included a series of studies performed over an expansive time period that contained fundamental differences in management techniques, creating a significant level of clinical heterogeneity, and causing the conclusions of the reviewed literature to be of questionable significance to our needs. Therefore, we deemed it reasonable to exclude this type of literature from our review and rely instead on relevant randomized controlled trials (RCTs) and the expert opinions of physicians and other medical personnel as expressed through the recommendations of professional societies, clinical practice guidelines and the like to answer our evidence questions.

The patient population investigated was required to consist of either those individuals with stable COPD or those individuals' status post an acute exacerbation of previously diagnosed COPD. Trials in which these patient populations were mixed were not considered unless subgroup results were reported. We excluded literature in which patients with obstructive sleep apnea were studied, documented either by polysomnography or clinical evaluation. Outcomes were required to be followed for at least six months, with our primary interest directed towards mortality/survival data as well as repeat exacerbation/hospitalization data. Other outcomes of interest included adherence to NIV therapy in the home as well as changes in PaCO₂ and quality of life measures.

Comparators were standard /usual care. So as not to confound our results, we excluded trials in which the usual care comparator specified such treatments as exercise programs or pulmonary rehabilitation programs. However, because of the widespread need for long term oxygen therapy (LTOT) in patients with COPD, we did allow trials that evaluated NIPPV with/without the addition of this therapy.

There were no date constraints placed on the RCTs considered applicable to our evidence review. Professional society guidelines from 2019 forward were also consulted. Only English language literature was considered.

Below are two evidence tables. Table 1 contains data summarized from two articles pertaining to patients with stable COPD. Table 2 contains data also summarized from two articles, pertaining to patients with a recent exacerbation of COPD. Furthermore, in Section VII of this NCA are the summaries of four professional society guidelines and two professional society position papers, as well as the findings of a pertinent Medicare Evidence Development & Coverage Advisory Committee Meeting and supporting Technology Assessment. The full citation for these publications can be found in the bibliography of this proposed decision memorandum.

Table 1. Data Summary for Patients with Stable COPD (2 studies)

Reference Groups (N) Follow-up	Initial device setting Backup rate (bpm) Prescribed use	Effectiveness outcome at follow-up, unless otherwise noted Intervention vs. Comparator
Köhnlein et al., 2014 Study Goal: To investigate the effect of long term NPPV targeted to markedly reduce hypercapnia, on survival of patients with advanced, stable hypercapnia NIPPV (102) vs. optimal medical therapy (93)	Initial device setting: Pressure support targeted to reduce baseline PaCO ₂ by ≥ 20% or achieve PaCO ₂ values < 6.5 kPa. High backup rates were preferred, but assisted ventilation was also acceptable if patients could not tolerate high backup rates Mean backup rate (SD): 16.1 (3.6) Prescribed use: 6 hours/day	<u>Hospitalization and mortality:</u> Mortality, n (%): 12 (12) vs. 31 (33), HR (95% CI) 0.24 (0.11–0.49) (P) Emergency hospital admissions per patient, M (SD): 2.2 (10.2) vs. 3.1 (5.4) <u>Change in lung function, Intervention-Comparator (95% CI):</u> PaCO₂, %: -5.1 (-6.8 to -3.4) p < 0.0001

Reference Groups (N) Follow-up	Initial device setting Backup rate (bpm) Prescribed use	Effectiveness outcome at follow-up, unless otherwise noted Intervention vs. Comparator
Mean age NPPV: 62.2±8.6; Control: 64.4 ± 8.0 Mean BMI: NPPV 24.8+ <u>5.8</u> ; Control: 24.5 +5.8 Follow-up: 12 months		PaO ₂ , %: 0.8 (−1.6 to 3.1) p = 0.53 HCO ₃ , %: −3.0 (−4.6 to −1.5) p = 0.00018 FVC, %: −0.3 (−3.1 to 2.5) p = 0.83 RV/TLC, %: −0.2 (1.4 to 1.1) p = 0.81 PH: 0.015 (0.025 to 0.004) p = 0.0056 <u>Mean change in HRQoL scores, Intervention-Comparator (95% CI):</u> SF-36, General Health Perception: 8.6 (1.8-13.3), p = 0.0289 SRQ summary: 5.6 (0.1–1.1) p = 0.0445
Clini et al., 2002 Study Goal: Assess the effect of the addition of NIPPV to LTOT to LTOT alone on severity of hypercapnia, use of healthcare resources and HRQoL. NIPPV (43) vs. optimal medical therapy (47) Mean age NIPPV: 64 ±7; LTOT: 66 ±14 BMI NIPPV: 26±5 BMI LTOT: 5±6 Follow-up: 2 years	Initial device setting: S/T mode at the maximal tolerated IPAP and at an EPAP tolerated in the range of 2–5 cmH ₂ O. Oxygen was added to achieve SaO ₂ of 90%. Patients needed to spend >90% of recording time with SaO ₂ ≥ 90% under NIPPV Backup rate: 8 Prescribed use: ≥ 5 hours/night	<u>Hospitalization and mortality:</u> Mortality rate, %: 18 vs. 17 Hospital admissions, M (SD): 0.9 (1.2) vs. 1.4 (2.3) NS (P) ICU admissions, M (SD): 0.2 (0.4) vs. 0.4 (0.8) NS (P) Days in hospital, 3 years pre- vs. 2 years post-study start, Intervention vs. Comparator, treatment effect (95% CI): 6.996 (−4.30–18.29) p=0.2281 (P) <u>Lung function:</u> PaCO ₂ during usual oxygen breathing, Intervention - Comparator (95% CI): 4.270 (1.58–9.96) p = 0.002 (P) PaO ₂ during usual oxygen breathing: NS (P) PaO ₂ and PaCO ₂ during room air breathing: NS (P) FEV, % pred, M (SD): 27.5 (10.6) vs. 30.8 (11.1), NS VC, % pred, M (SD): 55.3 (18.2) vs. 59.8 (12.3); NS MIP, cmH ₂ O, M (SD): 50.6 (20.6) vs. 48.1 (27.2) NS <u>Mean change in HRQoL scores, Intervention-Comparator (95% CI):</u> SRGQ: p = 0.554 NS (P) MRF-28, treatment effect: 7.100 (0.13-0.47) p = 0.04 (P) Sleep quality score (1 is best, 4 is worst): 0.31 (0.1–1.0) MRC dyspnea: 0.600 (0.15–1.05) p = 0.013 6MWD, meters: 183 (118) vs. 232 (111) NS
Köhnlein T, Windisch W, Köhler D, Drabik A, Geiseler J, Hartl S, Karg O, Laier-Groeneveld G, Nava S, Schönhofer B, Schucher B, Wegscheider K, Criée CP, Welte T. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014 Sep;2(9):698-705. doi: 10.1016/S2213-2600(14)70153-5. Epub 2014 Jul 24. PMID: 25066329.		
Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N; Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002 Sep;20(3):529-38. doi: 10.1183/09031936.02.02162001. Erratum in: Eur Respir J. 2002 Dec;20(6):1617. PMID: 12358325.		
Abbreviations: 6MWD: 6-minute walk distance; CRQ: Chronic Respiratory Disease Questionnaire; bpm: breaths per minute; FEV: forced expiratory volume; FVC: forced vital capacity; GARS: Groningen Activity and Restriction Scale; HADS: Hospital Anxiety and Depression scale; HCO ₃ : bicarbonate; HR: hazard ratio; HRQoL: health-related quality of life; ICU: intensive care unit; MIP: maximal inspiratory pressure; MRC: Medical Research Council; MRF-28: Maugeri Respiratory Failure questionnaire; NIF: negative inspiratory force; NIPPV: non-invasive positive pressure ventilation; PaCO ₂ : partial pressure of carbon dioxide; PH: pulmonary hypertension; PSQI: Pittsburgh Sleep Quality Index; RV/TLC: Residual volume/total lung capacity; SRI: Severe Respiratory Insufficiency questionnaire; SRQ: Severe Respiratory Questionnaire; S/T: spontaneous/timed; TDI: Transitional Dyspnea Index; VC: vital capacity. Note: Intermediary outcomes before final follow-up were omitted from table. Significant differences between the Intervention and Comparator groups are in bold . All significant findings favor the Intervention group. ¹ P after an outcome indicates that this is a primary outcome; all other outcomes are secondary or exploratory outcomes.		

Table 2: Data Summary for Patients Post-Acute Exacerbation of COPD (2 studies)

Reference Groups Follow-up	Device setting Backup Rate (bpm) Prescribed use	Effectiveness Outcome Change (difference from baseline to follow-up) or Intervention vs. Comparator at follow-up, unless otherwise noted
<p>Murphy et al., 2017</p> <p>Study Goal: to investigate the effect of home NIV + oxygen on time to readmission/death in patients with persistent hypercapnia after an acute COPD exacerbation</p> <p>NIPPV (57) vs. long-term oxygen therapy (59)</p> <p>Mean age NIV: 66.4±10.2; Home Oxygen: 67.1±9.0</p> <p>Mean BMI (median (IQR) NIV: 21.5 (18.8-24.5); Home Oxygen: 22.2(17.9-26.9)</p> <p>Follow-up: Median (IQR): NIV: 12.2 months (8.9-12.9) vs. Home oxygen: 8.1 months (2.3-12.6)</p>	<p>Device setting: Daytime NIPPV acclimatization followed by nocturnal titration with O₂ entrained at the daytime prescription rate to achieve control of nocturnal hypoventilation with a high-pressure ventilation strategy.</p> <p>Backup rate: 14-16</p> <p>Prescribed use: O₂ therapy ≥15 hours/daily (both groups); NIPPV ≥6 hours/nightly</p>	<p><u>Hospitalization and mortality, aHR (95% CI):</u> Risk of readmission or death: 0.49 (0.31-0.77) p = 0.002 (P) 28-day readmission rate: 0.26 (0.11-0.61) p = 0.002 All-cause mortality: aHR: 0.67 (0.34-1.30) p = 0.23 Acute COPD exacerbations per year: 0.66 (0.46-0.9) p = 0.03</p> <p><u>Lung function, mm Hg, Intervention-Comparator, adjusted (95% CI):</u> Nocturnal transcutaneous CO₂: -10.7 (-16.4 to -5.1) p < 0.001 Daytime PaCO₂: -2.3 (-6.5 to 1.9) p = 0.28 Daytime PAO₂: -0.1 (-5.3 to 5.3) p = 0.99</p> <p><u>Treatment effects for HRQoL, Intervention-Comparator, adjusted (95% CI):</u> SRI: -0.4 (-5.4 to 4.7) p = 0.89 SGRQ (high is worse): 2.3 (-2.6 to 7.1) p = 0.36</p>
<p>Struik et al. 2014</p> <p>Goal of Study: To investigate if nocturnal NIV in COPD patients with prolonged hypercapnia after acute respiratory failure increases the time to readmission for respiratory causes or death</p> <p>NIPPV (101) vs. optimal medical therapy (100)</p> <p>Mean age NIV: 63.9± 8.6; Controls: 63.5±7.9</p> <p>Mean BMI NIV: 24.4 ±5.4; Controls : 24.8±6.3</p> <p>Follow-up: 12 months</p>	<p>Device setting: BIPAP S/T with a low backup rate of 12 bpm and an IPAP of 14 cm H₂O that was gradually increased to a maximal tolerated level. EPAP was started at 4 cm H₂O and increased if auto-PEEP was present or when patients used respiratory muscles to trigger the ventilator. The respiratory rate was set as close as possible to that of the patient. Inspiration to expiration time was 1:3, with a short rise time and titrated on comfort and effectiveness.</p> <p>Backup rate: 12 (initially)</p> <p>Prescribed use: 5 hours/night</p>	<p><u>Hospitalization and mortality:</u> Recurrent severe COPD exacerbation with hypercapnic ARF resulting in NIPPV, intubation, or death, %: 38.5 vs. 60.2 p = 0.039 (P) Mean days to hospitalization or death: 192 vs. 198 p = 0.85 Hospital readmissions, median (range): 1 (0-9) vs. 1 (0-6) p = 0.23 Total days in the hospital, median (range): 7.0 (0-107) vs. 3.5 (0-77) p = 0.087 Exacerbations at home, median (range): 1.0 (0-9) vs. 2.0 (0-14) p = 0.26</p> <p><u>Mean change in lung function, Intervention-Comparator (95% CI):</u> PH: 0.030 (0.005 to 0.050) p < 0.05 PaCO₂, kPa: -0.2 (-0.6 to 0.3) NS PaO₂, Pa: -0.3 (-1.2 to 0.6) NS HCO₃, mmol/L: 1.0 (-1.2 to 3.3) NS Base excess: 1.0 (-0.8 to 2.8) NS Saturation (%): -0.5 (-3.9 to 2.8) NS FEV1, liters: -0.024 (-0.12 to 0.07) NS VC, liters: -0.036 (-0.31 to 0.23), NS</p> <p><u>HRQoL score treatment effects (95% CI):</u> CCQ total: -0.04 (-0.5 to 0.4) NS MRF-28 total: -1.5 (-8.6 to 5.7) NS CRQ total: 0.01 (-0.4 to 0.4) NS SRI total: 4.8 (-0.1 to 9.7) NS GARS total: 0.4 (-2.3 to 3.0) NS HADS total: -1.3 (-4.1 to 1.6) NS MRC dyspnea: -0.05 (-0.6 to 0.5) NS</p>
<p>Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, Dowson L, Duffy N, Gibson GJ, Hughes PD, Hurst JR, Lewis KE, Mukherjee R, Nickol A, Oscroft N, Patout M, Pepperell J, Smith I, Stradling JR, Wedzicha JA, Polkey MI, Elliott MW, Hart N. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2017 Jun 6;317(21):2177-2186. doi: 10.1001/jama.2017.4451. PMID: 28528348; PMCID: PMC5710342.</p> <p>Struik FM, Sprooten RT, Kerstjens HA, Bladder G, Zijnen M, Asin J, Cobben NA, Vonk JM, Wijkstra PJ. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax. 2014 Sep;69(9):826-34. doi: 10.1136/thoraxjnl-2014-205126. Epub 2014 Apr 29. PMID: 24781217.</p>		

Reference Groups Follow-up	Device setting Backup Rate (bpm) Prescribed use	Effectiveness Outcome Change (difference from baseline to follow-up) or Intervention vs. Comparator at follow-up, unless otherwise noted
<p>Abbreviations: aHR: adjusted hazard ratio; ARF: acute respiratory failure; bpm: breaths per minute; CCQ: Clinical COPD Questionnaire; CO₂: carbon dioxide; CPAP: continuous positive airway pressure; CRQ: Chronic Respiratory Disease Questionnaire; EPAP: expiratory positive airway pressure; GARS: Groningen Activity and Restriction Scale; HADS: Hospital Anxiety and Depression scale; HR: hazard ratio; HRQoL: health-related quality of life; IQR: interquartile range; IPAP: inspiratory positive airway pressure; LTOT: long-term oxygen therapy; MRF-28: Maugeri Respiratory Failure questionnaire; MRC: Medical Research Council; NIPPV: non-invasive positive pressure ventilation; O₂: oxygen; OMT: optimal medical therapy; PaCO₂: partial pressure of carbon dioxide; PaO₂: partial pressure of oxygen; PH: pulmonary hypertension SRI: Severe Respiratory Insufficiency Questionnaire; PEEP: positive end-expiratory pressure; SGRQ: St. George Respiratory Questionnaire.</p> <p>Note: Intermediary outcomes before final follow-up were omitted from table. Significant differences between the Intervention and Comparator groups are in bold. All significant findings favor the Intervention group. ¹P after an outcome indicates that this is a primary outcome; all other outcomes are secondary or exploratory outcomes.</p>		

4. Medicare Evidence Development & Coverage Advisory Committee (MEDCAC)

A virtual MEDCAC meeting was convened on July 22, 2020, to examine the scientific evidence pertaining to the use of various types of NIPPV equipment in order to assess the characteristics that define the patient selection criteria, usage parameters, concomitant services, and equipment parameters necessary to best achieve positive patient health outcomes in beneficiaries with CRF consequent to COPD. The devices considered were HMs, BPAP devices and continuous positive airway pressure (CPAP) devices. The outcomes of interest included decreased mortality, decreased frequency of exacerbations requiring emergency room or hospital admission, increased time to hospital re-admission for respiratory related disease, and improved function and quality of life. The complete transcript of the meeting can be found at <https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/downloads/id77c.pdf>.

Based on a score system where (1) indicates low confidence, (3) indicates intermediate confidence and (5) indicates high confidence, the MEDCAC Panel voted on the following questions to demonstrate their opinions on the evidence discussed during the meeting:

1. How confident are you that the evidence is sufficient to determine the patient selection criteria that will improve health outcomes (e.g. laboratory values, co-morbidities, frequency of exacerbations requiring ER or hospital admission, hospital discharge timing, pulmonary function tests, etc.) when used with any category of home NIPPV device? Overall average score = 3.15^[1]
2. How confident are you that the evidence is sufficient to determine the NIPPV equipment parameters necessary to promote successful patient-related outcomes (e.g. decreased mortality, decreased frequency of exacerbations requiring ER or hospital admission, increased time to hospital re-admission for respiratory related disease, and improved physical function and quality of life)? Overall average score = 2.85
3. How confident are you that any improved patient-related outcomes noted above made with any type of NIPPV device in the home, can be attributed to the use of the equipment alone as opposed to the concomitant provision of other support services like home respiratory therapists, home medication reconciliation and repeated elective hospital admissions? Overall average score = 2.23
4. How confident are you that the evidence is sufficient to provide the patient usage parameters that are necessary to achieve the successful patient outcomes in Q2? Overall average score = 2.38

Evidence-Based Guidelines

A search for evidence-based guidelines identified the following :

The European Respiratory Society Guideline

Ergan B, Oczkowski S, Rochweg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. *Eur Respir J*. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. PMID: 31467119.

The European Respiratory Society (ERS) created a task force to develop guidelines aimed at providing evidence-based recommendations on the use of long term home noninvasive ventilation (LTH-NIV) for patients with hypercapnic COPD. The task force consisted of clinical experts in the field of noninvasive ventilation as well as clinicians representing the ERS Assemblies of Respiratory Intensive Care, Sleep and Breathing Disorders, and Clinical Physiology. Additionally, methodologists with experience in evidence synthesis and guideline development using GRADE methodology were present on the taskforce as was a representative from the European Lung Foundation who reported on the patient perspectives gathered from a home mechanical ventilation survey. The taskforce generated four PICO (target population-intervention-comparator-outcome) questions to aid in the accomplishment of their goal. Based on those questions, the following recommendations were offered:

- The ERS task force suggested LTH-NIV be used for patients with chronic stable hypercapnic COPD (conditional recommendation, low certainty evidence).
- The ERS task force suggested LTH-NIV be used in patients with COPD following a life-threatening episode of acute hypercapnic respiratory failure requiring acute NIV, if hypercapnia persists following the episode (conditional recommendation, low certainty evidence).
- The ERS task force suggested titrating LTH-NIV to normalize or reduce PaCO₂ levels in patients with COPD (conditional recommendation, very low certainty evidence).
- The ERS task force suggested using fixed pressure support mode as first-choice ventilator mode in patients with COPD using LTH-NIV (conditional recommendation, very low certainty evidence).

The task force highlighted the generalized uncertainty surrounding the evidence for these recommendations. Therefore, it stated that the recommendations would require consideration of individual preferences, resource considerations, technical expertise availability, and the clinical circumstances of the patient prior to implementation of their suggestions. In all, different choices are likely to be appropriate for different patients and the treatments prescribed should be tailored to individual circumstances, values and preferences.

The task force also discussed various issues other than the above, which they believed impacted the effectiveness of long-term noninvasive ventilation in COPD. Among these topics was the subject of adherence to therapy. After consideration of the available evidence, the task force stated that five hours of long term home noninvasive therapy per day would be a reasonable target, though it noted that if patients do not achieve this amount of treatment time, they may still receive clinical benefit. Moreover, the task force recommended that ventilators without a battery "...will be used when NIV is used for less time in each 24-hour period. If the patient uses it for a longer duration (approximately 12 h per day, depending on individual circumstances) a ventilator with internal battery should be considered."

The Canadian Thoracic Society Clinical Practice Guideline

Kaminska M, Rimmer KP, McKim DA, Nonoyama M, Giannouli E, Morrison DL, O'Connell C, Petrof BJ & Maltais F (2021): Long-term non-invasive ventilation in patients with chronic obstructive pulmonary disease (COPD): 2021 Canadian Thoracic Society Clinical Practice Guideline update, *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, DOI: 10.1080/24745332.2021.1911218

The objective of the Canadian Thoracic Society Clinical Practice Guideline was to provide updated clinical recommendations regarding the use and optimization of long-term NIV in the treatment of patients with severe chronic hypercapnic respiratory failure of COPD (FEV1 < 50% predicted). The guideline was focused on two target groups: (1) individuals with severe COPD and hypercapnia who were stable and (2) individuals with COPD and persistent hypercapnia following a severe COPD exacerbation that required NIV in the acute setting. The guideline panel was comprised of seven adult respirologists, one physiatrist who specialized in neuro-rehabilitation and one respiratory therapist. Searches were conducted for English language RCTs published between June 1, 2010 through November, 2020. The topic of chronic hypercapnia in COPD and concomitant sleep apnea or obesity related hypoventilation was not considered. The Cochrane Risk of Bias Tool for RCTs was used to assess the risk of bias in individual studies. GRADE evidence profiles were developed to rate the certainty of evidence.

The Guidelines made the following recommendations:

- In patients with stable severe COPD and chronic hypercapnic respiratory failure (PaCO₂ ≥ 52 mmHg), it was suggested that long-term NIV be used to improve survival (SOE: weak/conditional; low certainty).
- In patients with severe COPD on LTOT who remain significantly hypercapnic (persistent PaCO₂ ≥ 52 mmHg) at least 2 weeks after discontinuing NIV for an acute exacerbation, it was suggested that long-term NIV be used to delay hospital readmission (SOE: weak/conditional; very low certainty).
- When applying long term NIV to patients with COPD and chronic hypercapnic respiratory failure (persistent PaCO₂ ≥ 52 mmHg) it was suggested that high-intensity NIV instead of low-intensity NIV be used to improve PaCO₂ (SOE: weak/conditional; low certainty).
- The Guidelines did not recommend the use of volume assured pressure-preset NIV over standard pressure-preset NIV in patients with COPD and chronic hypercapnic respiratory failure (SOE: strong; low certainty).

The authors noted that this 2021 guideline update demonstrated a significant shift in the approach to long-term NIV in patients with COPD and chronic hypercapnic respiratory failure, moving from a previous 2011 recommendation of not using this treatment option in most circumstances to a favorable (though weak/conditional) recommendation for its use in particular contexts. Specifically, it is recommended that it is important to offer this therapy in line with patient preferences where long-term NIV will be utilized for more than five hours per day and in whom it is successful in reducing PaCO₂ and in controlling nocturnal hypoventilation. Further research was encouraged.

American Thoracic Society Clinical Practice Guideline

Macrea M, Oczkowski S, Rochweg B, Branson RD, Celli B, Coleman JM 3rd, Hess DR, Knight SL, Ohar JA, Orr JE, Piper AJ, Punjabi NM, Rahangdale S, Wijkstra PJ, Yim-Yeh S, Drummond MB, Owens RL. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020 Aug 15;202(4):e74-e87. doi: 10.1164/rccm.202006-2382ST. PMID: 32795139; PMCID: PMC7427384.

These clinical practice guidelines regarding the use of NIV (bi-level positive airway pressure) were prepared on behalf of the American Thoracic Society Assembly on Sleep and Respiratory Neurobiology. The panel consisted of 12 physicians and 2 respiratory therapists with expertise in the field of domiciliary NIV and/or COPD. Also included on the panel were two clinician-methodologists with experience in evidence synthesis and guideline development using GRADE (Grading of Recommendations, Assessment, Development and Evaluation methodology). There was also participation of patient partners to aid in question selection and outcome prioritization.

The panel prioritized 5 PICO (patients, intervention, comparator and outcome) questions for the guideline to address. Medical librarians and the two methodologists conducted searches for English language observational trials, RCTs and systematic reviews for each PICO question in various databases from inception to April 2019. The direction and strength of recommendations were decided by consensus.

For patients with chronic (FEV1/FVC < 0.70; resting PaCO₂ > 45 mm Hg; not during exacerbation) hypercapnic respiratory failure due to chronic obstructive pulmonary disease,

1. The panel suggested the use of nocturnal NIV in addition to usual care for patients with chronic stable hypercapnic COPD (conditional recommendation, moderate certainty).
2. The panel suggested that patients with chronic stable hypercapnic COPD undergo screening for OSA before initiation of long-term NIV (conditional recommendation, very low certainty).
3. The panel suggested not using in-hospital initiation of long-term NIV during an episode of acute-on-chronic hypercapnic respiratory failure, favoring instead reassessment for NIV at 2-4 weeks after resolution (conditional recommendation, low certainty).
4. The panel suggested not using an in-laboratory overnight polysomnogram (PSG) to titrate NIV in patients with chronic stable hypercapnic COPD who are initiating NIV (conditional recommendation, very low certainty).

5. The panel suggested NIV with targeted normalization of PaCO₂, in patients with hypercapnic COPD on long-term NIV (conditional recommendation, low certainty).

Despite these recommendations, the Panel noted that many issues surrounding the provision of NIV for patients with stable hypercapnic COPD remained to be considered. For example, the studies reviewed to support the recommendations excluded individuals with known obstructive sleep apnea and/or severe obesity. The studies also were found to frequently initiate NIV in the hospital as opposed to the home; an approach that may not mimic real world clinical practice. Additionally medical expertise in NIV may be lacking in certain areas of the country, thereby establishing conditions for potential healthcare disparities. These and other limitations of the available research suggested to the Panel that further research is needed to help determine the optimal management of those patients who might benefit from NIV.

Swiss Society of Pulmonology

Janssens JP, Michel F, Schwarz EI, Prella M, Bloch K, Adler D, Brill AK, Geenens A, Karrer W, Ognà A, Ott S, Rüdiger J, Schoch OD, Soler M, Strobel W, Uldry C, Gex G; on behalf of the Special Interest Group on Ventilation and Oxygen Therapy of the Swiss Society of Pneumology. Long-Term Mechanical Ventilation: Recommendations of the Swiss Society of Pulmonology. *Respiration*. 2020 Dec 10;1-36. doi: 10.1159/000510086. Epub ahead of print. PMID: 33302274.

The Swiss Society of Pulmonology (SSP) and the Swiss Society of Pediatric Pulmonology published recommendations on home mechanical ventilation. This narrative review included the most recent recommendations of the group based on an extensive review of the medical literature through PubMed over the past 10 years, of other national guidelines, and of the specifics of care for long-term HMV in Switzerland. The final text was discussed among the members of the Special Interest Group on HMV (SIG) to reach a consensus. The text focuses on HMV provided at home or in long-term care institutions. In long-term NIV, bi-level positive pressure support ventilation in spontaneous/timed mode is noted to be the most commonly used mode in clinical practice. Therefore, the recommendations presented focus on this mode.

Based on the evidence and the recent guidelines published by the ERS task force on NIV in COPD, the SIG suggested the following recommendations (all conditional):

- Long-term NIV should be used in chronic stable hypercapnic patients (PaCO₂ > 7 kPa [52.5 mm Hg]) with severe COPD.
- Long-term NIV should be implemented after an acute episode of hypercapnic respiratory failure only if hypercapnia (PaCO₂ > 7 kPa [52.5 mm Hg]) persists 2–4 weeks after the acute episode.
- The potential benefit of long-term NIV for a recurrent acute episode of hypercapnic respiratory failure without persistent hypercapnia at 2–4 weeks remains undetermined.
- When implementing NIV in COPD patients with chronic hypercapnic respiratory failure, settings should be adjusted to decrease PaCO₂ below 6.5 kPa (50 mm Hg) or reduce PaCO₂ levels by more than 20% of baseline level.
- When implementing NIV in COPD patients with chronic hypercapnic respiratory failure, fixed pressure support ventilation should be preferred to auto-titrating modes as first-choice mode.

CMS also considered the following professional society position statements for this proposed decision.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program

Global Initiative for Chronic Obstructive Lung Disease 2025 Report. Accessed December 18, 2024 at: https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was begun in 1998 with the aim of producing recommendations for the management of COPD based on the best scientific evidence available. The GOLD Science Committee, an invited group of volunteers recognized as leaders in the field of COPD clinical practice and research, reviews published material regarding the prevention and management of COPD, in order to provide recommendations to diagnose, assess and treat the disease.

The 2025 GOLD Report comments that noninvasive ventilation is occasionally used in patients with stable very severe COPD. Whether to use NIPPV chronically at home to treat patients with acute on chronic respiratory failure after hospitalization is undetermined and may be influenced by persistent hypercapnia.

However, in patients with both COPD and obstructive sleep apnea, the Report states that there are clear benefits to the use of CPAP to improve both survival and the risk of hospital admissions.

Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society

Hill NS, Criner GJ, Branson RD, Celli BR, MacIntyre NR, Sergew A; ONMAP Technical Expert Panel. Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. *Chest*. 2021 Nov;160(5):e389-e397. doi: 10.1016/j.chest.2021.06.082. Epub 2021 Jul 30. PMID: 34339684; PMCID: PMC8628175.

The American College of Chest Physicians, the American Academy of Sleep Medicine, the American Association for Respiratory Care and the American Thoracic Society developed and published a Technical Expert Panel (TEP) report on recommendations to revise CMS policies regarding the delivery of NIV therapy to Medicare beneficiaries.

The following recommendations regarding coverage of BPAP devices and HMVs for those individuals with COPD were applicable to consideration in this NCA:

- Removal of the current requirement for a nocturnal oximetry study using either 2L/min nasal oxygen or the patient's usual FiO₂ (whichever is higher) to qualify for a RAD.
- Removal of the requirement that patients start with a BPAP device without a backup rate before they are eligible for a BPAP device with backup rate.

For individuals with severe COPD, all of the following criteria need to be satisfied:

- Require an ABG while awake and receiving supplemental oxygen (if prescribed) displaying a PaCO₂ ≥ 52 mm Hg for initiation of BPAP therapy.
- Require OSA and CPAP treatment to have been considered and ruled out prior to receipt of BPAP device (formal testing not required; this only requires clinical documentation).
- Consider the use of an HMV for patients with severe hypercapnic COPD who:
 - Require higher inspiratory pressures than those deliverable by E0471 [respiratory assist device, bi-level pressure capability, with backup rate feature, used with noninvasive interface, e.g. nasal or facial mask (intermittent assist device with continuous positive airway pressure device)] or,
 - Require FiO₂ higher than 40% or 5 L/min nasally or,
 - Require device support for 10 h per day or greater (i.e., daytime use) or,
 - Require both sophisticated alarms and accompanying internal battery (high-dependency patient) or,
 - Require mouthpiece ventilation during the day or,
 - Demonstrate persistence of hypercapnia with PaCO₂ ≥ 52 mm Hg despite adequate adherence to BPAP therapy.

It was also recommended that a second 90-day trial period be covered for those patients not meeting the current adherence requirements^[2] for continued coverage who return at least twice to a treating physician and see benefit from continued use. Furthermore, it was recommended that rehospitalization would constitute criteria for a new HMV initiation trial even in those previously failing to meet adherence criteria.

The TEP also concluded that the expertise of experienced clinicians (e.g. respiratory therapists) to provide home support for individuals receiving home NIV is critical to patient care whether that patient is using a RAD or HMV in the home.

VIII. Public Comment

Public comments sometimes cite the published clinical evidence and give CMS useful information. Public comments that give information on unpublished evidence such as the results of individual practitioners or patients are less rigorous and therefore less useful for making a coverage determination.

Public comments that contain personal health information will be redacted or will not be made available to the public on the CMS website. CMS responds in detail to the public comments on a proposed decision when issuing the final decision memorandum. All comments that are submitted without personal health information may be viewed in their entirety by using the following link <https://www.cms.gov/medicare-coverage-database/view/ncacal-public-comments.aspx?ncid=315&ncacaldoctype=all&status=all&sortBy=status&bc=17>.

Initial Comment Period: 9/11/2024-10/11/2024

During the initial 30-day public comment period following the release of the tracking sheet, CMS received 72 comments. The majority of commenters were supportive of an NCD for the use of noninvasive respiratory assist devices (RADs) and home mechanical ventilators (HMs) for the treatment of chronic respiratory failure (CRF) consequent to COPD. Six comments requested the NCD process be paused until the durable medical equipment (DME) Medicare Administrative Contractors (MACs) complete their review of the current LCD for respiratory assist devices.

The majority of comments were provided by physicians. Other comments were provided by respiratory therapists, DME providers, device manufacturers, professors, and healthcare companies. Eight comments were provided by national associations/professional organizations/coalitions including American Association for Respiratory Care (AARC), American Academy of Sleep Medicine (AASM), American Association for Homecare (AAHomecare), Advanced Medical Technology Association (AdvaMed), American Thoracic Society (ATS), American College of Chest Physicians (CHEST), Council for Quality Respiratory Care (CCRQ), and the COPD Foundation. One comment was provided by the requestor, the Optimal Noninvasive Ventilation Medicare Access Promotion Technical Expert Panel (TEP) consisting of representatives from the American College of Chest Physicians, the American Academy of Sleep Medicine, the American Association for Respiratory Care, and the American Thoracic Society.

Numerous commenters provided references for our deliberation of this NCA. We appreciate this information. All such references were assessed for inclusion in our evidence review.

Second Comment Period: 3/11/2025-4/10/2025

During the second 30-day public comment period, CMS received 199 comments. While the majority of commenters were supportive of establishing clear coverage criteria for noninvasive RADs and HMVs for the treatment of CRF consequent to COPD, some had concerns with the initial coverage and continuing usage criteria. The commenters stated the NCD will inadvertently create barriers to patient access. Several comments preferred keeping the current LCD for RADs rather than finalizing the proposed criteria, if the criteria was not modified. The commenters were supportive of eliminating overnight oximetry, not requiring formal sleep testing and the provision of an additional interface (mask) if daytime ventilation is needed. All comments submitted

during the comment period without personal health information may be viewed by using the following link: <https://www.cms.gov/medicare-coverage-database/view/ncacal-public-comments.aspx?ncaid=315&ncacaldoctype=all&status=all&sortBy=status&bc=17>.

The majority of comments were provided by respiratory therapists and DME suppliers, including similar letters from multiple employees of the same company. Comments were also provided by other clinicians, device medical technology manufacturers, healthcare systems, and professors. We received one comment from a health policy and economics consulting firm, one comment from a CPAP adherence program, and one comment from a former Medicare program integrity analyst. Fifteen comments did not provide their titles and/or organizations. Eight comments were provided by national and state associations, professional societies and organizations including Association of Pulmonary Advanced Practice Providers (APAPP), American College of Chest Physicians (CHEST), American Association for Homecare (AAHomecare), American Association for Respiratory Care (AARC), California Association of Medical Product Suppliers (CAMPS), American Academy of Sleep Medicine (AASM), American Thoracic Society (ATS), and the COPD Foundation. One comment was provided by a coalition of home oxygen therapy providers and manufacturing companies, the Council for Quality Respiratory Care (CCRQ). One comment was provided by the requestor, the Optimal Noninvasive Ventilation Medicare Access Promotion Technical Expert Panel (TEP) consisting of representatives from the American College of Chest Physicians, the American Academy of Sleep Medicine, the American Association for Respiratory Care, and the American Thoracic Society.

Numerous commenters provided references for our deliberation of this NCA. All such references were assessed for inclusion in our evidence review.

Initial Coverage Criteria

Comment: Many commenters expressed concern that the values defining the high intensity therapy provided by a RAD with backup rate feature would be required at the initiation of the patient's usage of the device.

Response: We added language to clarify that patients must meet the parameters of high intensity therapy by the 6th month after the initial usage of a RAD with backup rate feature. These initial coverage criteria are for patients new to the use of a RAD with backup rate feature to titrate up to (or go beyond if appropriate) the IPAP, respiratory rate and duration values that meet the Medicare coverage criteria. As described in the analysis, though some investigations demonstrate acclimatization of patients to their high intensity therapy in a matter of days, many individuals (and particularly those who initiate their therapy at home) with COPD are expected to need months to titrate up to the values that meet the Medicare coverage criteria in Section I.

Comment: Many commenters requested that CMS remove the requirement for a RAD with backup rate feature to be utilized in the high intensity mode (IPAP > 20 cm H₂O and backup respiratory rate of at least 14 breaths per minute).

Response: As a treatment technique, the literature has shown the high intensity mode of NIV is of clinical value for appropriate COPD patients who experience hypercapnia. However, there is no exact definition of high intensity NIV and specifically there are no fixed determinants for the "high" pressure that accompanies this treatment therapy (Kaminska, Adam & Orr, 2024).

After considering the public comments, including comments from clinicians treating patients with COPD and balancing the comments with the evidence, we updated the coverage decision and we lowered the minimum criteria for high intensity therapy to be defined as an IPAP \geq 15 cmH₂O and back up rate of at least 14 breaths per minute. These parameters will provide a flexible, yet accessible therapy to clinicians treating patients.

Comment: Many commenters stated that individuals with COPD whose PaCO₂ values are 46-51 mmHg should be eligible for coverage of a RAD or HMV. The American Thoracic Society Clinical Practice Guidelines was often cited as the supporting source for this request (Macrea et al., 2020).

Response: We disagree. While we recognize that the ATS defines chronic hypercapnia in stable patients with COPD in the following manner: FEV₁/FVC less than 0.70; resting PaCO₂ greater than 45 mmHg; not during exacerbation, we note the ATS Clinical Practice Guideline identified the need for research to determine which patients (i.e., phenotypes) would be expected to benefit the most from NIV therapy. Furthermore, the European Respiratory Society guidelines (Ergaz et al., 2019) state that it is likely that a higher level of PaCO₂ at enrollment (referring to PaCO₂ values at a mean of 53 mmHg vs. those at 48 mmHg) are among the characteristics that were major determinants of the outcome of the HOT-HMV study described in this NCA. This Guideline noted that treatment response may be better in those stable hypercapnic patients whose PaCO₂ is greater than 50 mmHg (among other criteria).

Additionally, the 2021 Canadian Thoracic Society Clinical Practice Guideline update (Kaminska et al., 2021) specifically discusses the threshold PaCO₂ that should be used for selecting COPD candidates for long term NIV therapy. Citing various investigations, the guideline states that the opinion of the authoring panel is that "...data support long term NIV only for those chronically hypercapnic patients with COPD with PaCO₂ levels \geq 52 mmHg." (Referring to individuals with stable hypercapnic COPD). The panel went on to say that treating lower levels of hypercapnia may result in ventilating patients who would not benefit from the therapy, causing unnecessary burden to these patients. The panel suggested long term NIV to delay hospital readmission in patients with severe COPD on long term oxygen therapy who remain significantly hypercapnic (persistent PaCO₂ > 52mmHg) for at least 2 weeks after discontinuing NIV for an acute exacerbation.

Based on the totality of the evidence, the threshold value of a PaCO₂ of 52 mmHg is appropriate. We are finalizing as proposed.

Comment: Many commenters expressed concern that performing repetitive ABGs at NIV initiation and follow up is inappropriate. For example, it was stated that ABGs were painful for the patient and potentially difficult to access in rural hospitals. Commenters recommended that we revise this criterion to include less invasive methods, such as venous blood gases, end-tidal CO₂, and transcutaneous CO₂.

Response: The NCD does not require follow up ABGs. A PaCO₂ value \geq 52 mmHg, as determined by ABG, is necessary only before beginning the use of either a RAD or an HMV. No follow up ABGs are required. Requirements for continued coverage rest on daily duration of device usage and EITHER improvements in PaCO₂ values OR symptoms associated with chronic hypercapnia. Both are not required for continued coverage. We have reformatted coverage criteria to clarify.

The strengths and weaknesses of the various less invasive methods used to determine CO₂ levels are outside the scope of this NCD; coverage in such circumstances is left to MAC discretion.

Comment: Many commenters were concerned that arterial blood gases (ABGs) may not be obtainable in certain rural areas.

Response: In the event that an ABG cannot be obtained for initial coverage due to documented circumstances outside of the control of the clinician, (e.g., a lack of available laboratory services), we remind interested parties that coverage outside the NCD criteria is left to the Medicare Administrative Contractors (MACs) to make reasonable and necessary determinations under section 1862(a)(1)(A) of the Social Security Act for any beneficiary seeking coverage for RADs and HMVs used as treatment of chronic respiratory failure consequent to COPD.

Comment: Some commenters expressed concern that our language regarding sleep apnea may preclude the coverage of a RAD with backup rate feature for individuals with overlap syndrome. Other commenters requested that we clarify whether formal laboratory testing is required to rule out sleep apnea in the COPD patient.

Response: Formal sleep testing is not required if there is sufficient information in the medical record to demonstrate that the patient does not suffer from some form of sleep apnea as the predominant cause of awake hypercapnia or nocturnal arterial oxygen desaturation. Additional wording has been added to the NCD to clarify this requirement.

Comment: A few commenters have stated that the proposed initiation criterion denoting that the clinician establish that the patient or caregiver is capable of using the device should be deleted because the DMEPOS Quality Standards already address this issue.

Response: We agree. The DMEPOS Quality Standards state that the supplier must "ensure that the beneficiary and/or caregiver(s) can use all equipment and item(s) provided safely and effectively in the settings of anticipated use." The DMEPOS Quality Standards can be viewed at: <https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Downloads/Final-DMEPOS-Quality-Standards-Eff-01-09-2018.pdf> We agree that our coverage criterion in the proposed NCD that "the individual exhibits the physical and cognitive ability to support home ventilation or has a caregiver who can assist" (as applied to both RADs and HMVs) is duplicative of the DMEPOS Quality Standards provision, and have removed the criterion from the final NCD.

Comment: A few commenters requested that stable COPD be defined as no increase in or new onset of more than one respiratory symptom lasting 2 or more days and no change of pharmacological treatment during a 2-week period, rather than a 4-week period (as noted in the proposed NCD), before initiation of NIV. Commenters also expressed that this change in criterion for the initiation of a RAD with backup rate feature in those with stable COPD is reflective of clinical practice.

Response: We agree with these commenters. We revised the definition of stable COPD to include no change of pharmacological treatment during a 2-week period.

Comment: Some commenters have noted that delaying NIV treatment to reassess hypercapnia after two weeks post hospitalization for an exacerbation of COPD could put patients at risk. They believe there is strong evidence supporting early initiation of NIV, which reduces mortality, hospital readmissions, and healthcare costs.

Response:

The American Thoracic Society Clinical Practice Guideline (Macrea et al., 2020) and the 2021 Canadian Thoracic Society Clinical Practice Guideline (Kaminska et al., 2021) both suggest waiting for 2-4 weeks after resolution of an acute exacerbation and discontinuation of NIV use in the hospital to evaluate individuals for long term home device therapy. The Canadian Guideline specifically addresses patients on long term oxygen therapy. The European Respiratory guideline suggests that long term home NIV be used in patients after a life-threatening episode of hypercapnic respiratory failure requiring acute NIV, if the hypercapnia persists; it does not however place a time recommendation on this suggestion.

We reviewed the retrospective studies of Medicare claims data whose goal was to explore the clinical benefits associated with the use of HMVs in patients with chronic respiratory failure consequent to COPD as early as the first week following diagnosis. However, these studies did not meet our inclusion criteria for our evidence review. The studies' limitations weakened confidence in their conclusions. For example, while the authors used various statistical techniques to attempt to decrease bias, they could not obtain any information regarding patient compliance with the respiratory equipment of interest. Without taking compliance into account, the results obtained must be viewed with caution, as they would not provide strong evidence for the conclusions. A similar data report was submitted as a public comment. Though we appreciate the information, our concerns are the same as those discussed above. As a result, though the conclusions of the studies may be suggestive, they are not persuasive. The final NCD criterion was not revised.

It is important to note however, that literature and clinical experience both inform situations where it is medically appropriate for a patient to have access to either a RAD or HMV (depending on the beneficiary's individualized needs) at the time of hospital discharge. For example, the ATS Clinical Practice Guideline (Macrea et al., 2020) states (referring to their recommendation favoring reassessment for NIV at 2-4 weeks after resolution of a COPD exacerbation associated with acute on chronic respiratory failure): "These recommendations would not apply to those who remain persistently hypercapnic and cannot be 'weaned' from NIV in the hospital. In such patients, in-hospital continuation and transition to long-term NIV may be required."

Therefore, we are finalizing coverage of a RAD or an HMV when the beneficiary requires continuation of device usage to avoid rapidly developing signs and symptoms of severe chronic respiratory failure upon hospital discharge after an exacerbation of COPD.

Comment: A few commenters stated the coverage criterion that post-discharge home use must mirror the device used in the final 24 inpatient hours does not allow for clinical decision making in the best interest of the patient. Noting that patients often experience rapid respiratory shifts during recovery, commenters stated that physicians should retain the ability to adjust the type or settings of NIPPV devices post-discharge based on the evolving needs of the patient, not be locked into a device based on an arbitrary administrative timeframe.

Response: We agree. In contrast to individuals who can be successfully weaned from a hospital respiratory device after an acute COPD exacerbation, there is a subpopulation of patients when discharged, can reasonably be predicted to experience rapid symptom exacerbation or rise in PaCO₂, and possibly require a quick readmission. Our intent was to provide immediate access to the appropriate home respiratory device for these patients to avoid this pattern of events, including re-hospitalization.

For those patients who were successfully using a RAD in the hospital and fulfilled the criteria of a post-discharge device, we would expect them to be prescribed a similar RAD (i.e., with or without backup as they were using in the hospital). For those patients who were successfully using a ventilator in the hospital and fulfilled the criteria of the post-discharge device, we would expect either an HMV or RAD to be prescribed as determined by the treating clinician.

To make this clearer, we have revised the language of the NCD.

Comment: Many commenters stated that the NCD implied a stepped approach to therapy, that is, requiring failure on bilevel devices before initiating HMV.

Response: This was not the intent of the proposed NCD and the coverage criteria was revised to be clearer. It is not required that a RAD be associated with a therapy failure before an HMV is prescribed. If the treating clinician determines it's clinically appropriate to prescribe an HMV and not a RAD, there must be clear medical documentation of the clinical decision to demonstrate why the device is reasonable and necessary for the patient.

Comment: Commenters stated that the criterion, "reduction in COPD exacerbations requiring hospitalizations due, at least in part, to device usage has occurred" is unclear and requested removal.

Response: We agree with the commenters and removed this criterion in the final policy.

Comment: Some commenters stated that an $\text{FiO}_2 \geq 36\%$ (4L) is required to obtain an HMV and should be revised.

Response: Per the NCD, a $\text{FiO}_2 \geq 36\%$ or $\geq 4\text{L}$ nasally, is not necessarily a requirement for an HMV. Instead, it is one of several criteria that may be used to qualify a Medicare patient for an HMV.

Continuing Usage Criteria

Comment: Many commenters stated that home NIV users did not require follow up every six months.

Response: While we appreciate these comments, we are requiring that the practitioner evaluate and verify that the patient satisfies the applicable continuing usage criteria set forth in Sections (l)(B)(1)(b) and (l)(B)(1)(b) at least twice in the first year after device use is initiated to support continuing coverage of respiratory devices described in this NCD.

We believe this requirement is necessary to ensure that continued coverage by Medicare is warranted. However, we recognize that this may be burdensome to some patients. We remind treating clinicians that face to face visits are not required by this NCD.

Comment: Many commenters have objected to the proposed required usage of HMVs and RADs with and without backup rate feature, for treatment of COPD consequent to chronic respiratory failure for an average of at least 5 hours per 24-hour period. Instead, commenters cite the CMS "standard" of respiratory device compliance to be use of PAP ≥ 4 hours per night on 70% of nights during a consecutive thirty (30) day period anytime during the first three (3) months of initial usage.

Response: For any item to be covered by Medicare, it must (among other criteria) be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member (see 1862(a)(1)(A) of the Social Security Act). To assess the medical necessity of either a RAD or an HMV for any patient, both daily and long- term usage criteria must be evaluated to ensure the therapy improves the patient's health.

The cited "compliance standard" is from Local Coverage Decision 33718, which pertains to PAP Devices for the Treatment of Obstructive Sleep Apnea. This LCD doesn't cover RADs for diagnoses other than OSA and refers to LCD 33800 for such requirements. We don't consider the usage requirement in LCD 33718 to be a Medicare "standard." However, to reduce confusion among patients, clinicians, providers, and suppliers, who would need to follow different hourly benchmarks of NIV compliance for different diseases, we are revising the final NCD language to be similar to LCD 33718.

While we are revising this criterion, we note studies by Kohnlein et al., 2014 and Murphy et al., 2017, as well as two evidence-based guidelines (Ergan et al., 2019; Kaminska et al., 2021), suggest that NIV usage for at least five hours per day will likely provide clinical benefits, including delayed readmission times or improved survival in COPD patients. However, it is also recognized that (1) adherence to therapy is crucial to the efficacy of home NIV and (2) while five hours of NIV therapy daily may be a reasonable target, lesser amounts of NIV usage per 24 hours may still provide clinical benefit to the COPD patient (Ergan et al., 2019).

In summary, we revised the final NCD coverage adherence goal for NIV devices to be at least four hours per 24-hour period on at least 70% of days within the specified time periods in the NCD.

(Note: these time periods differ between the first evaluation and those that occur during the second evaluation and beyond. Within the first six months of device usage, NIV devices are to be used at least four hours per 24-hour period on a minimum of 70% of days during a 30-day period to accommodate the varying lengths of time that different patients will require to titrate up to four hours per 24-hour period of device usage on 70% of days thereafter. By the second evaluation period and beyond, patients must be using their devices at a consistent level, i.e., four hours per 24-hour period, on 70% of days in each paid rental period or any month in which supplies/accessories are dispensed.)

Comment: A few commenters have recommended that an acceptable outcome for the continued coverage of a RAD with backup rate feature includes "stabilization" of PaCO_2 .

Response: We agree and we updated the final coverage criteria. If all other coverage criteria are met, it is clinically appropriate to allow stabilization of a PaCO_2 value to be a criterion for continuing usage of a RAD if there is sufficient information to associate the interruption of the rising PaCO_2 values to the use of the NIV. Thus, we have revised Section (l)(B)(1)(b) to include stabilization of a PaCO_2 value as an outcome that may be used to justify continued coverage of a RAD with backup rate.

Comment: A few commenters suggested that sleep quality be added to the list of improved outcomes that may be used to justify continued coverage of a RAD (with or without backup).

Response: We agree and revised the coverage to add sleep quality. Sleep disturbance is common in the COPD population and can be extremely disruptive to quality of life. Severe COPD in particular may be associated with sleep complaints. Improvement in this symptom through NIV treatment may bring about a higher quality of life for the COPD patient (McNicholas, Verbraecken & Marin, 2013). Thus, we have revised Section (I)(B)(I)(b) to include improved sleep quality as an outcome that may be used to justify continued coverage of a RAD with backup rate.

General

Comment: Many commenters were concerned with how existing patient NIV equipment would be handled under the new NCD.

Response: Ventilators fall under “frequent and substantial servicing” of the DMEPOS benefit. CMS performs DMEPOS claim reviews using the policy that is in place at the time the item was initially provided. CMS will direct the MACs to focus claim reviews on claims where the initial claim for the item falls after the effective date of the new NCD.

The above does not restrict/limit applicable contractors from performing medical review where there is concern about potential fraud. Additionally, this does not impact the limited reviews that may be randomly conducted by the Comprehensive Error Rate Testing (CERT) contractor, per their statutory obligation.

Comment: Many commenters requested that the NCD be delayed until there can be more clinical input from the respiratory therapists and pulmonologists who care for these patients and prescribe NIV.

Response: CMS will not delay the NCD. CMS actively sought the input of many clinicians, including the clinicians mentioned in the comments. In 2020 CMS conducted a Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting. The MEDCAC Panel reviewed the Technology Assessment, specific to the home use of NIPPV by patients with CRF consequent to COPD. Devices considered included home mechanical ventilators and bi-level positive airway pressure devices. Guest panel members and speakers at the MEDCAC represented various viewpoints from the respiratory medicine field. For example, the MEDCAC panel and participants include experts in professional positions such as clinical professors of pulmonary medicine as well as members of CHEST, the American Thoracic Society, Chief Medical Officers of respiratory device supply companies, etc. The full MEDCAC transcript and related materials may be found at: <https://www.cms.gov/medicare-coverage-database/view/medcac-meeting.aspx?MEDCACId=77>.

Additionally, CMS performed its own internal review of the relevant literature and commissioned a targeted literature search of clinical trials relevant to this topic. Furthermore, we consulted two practicing pulmonologists to review the NCD for clinical relevancy.

Importantly, as is done during the development of all NCDs, CMS reviewed all public comments on the Proposed NCD and decision memorandum. One hundred ninety-nine comments were received on the proposed policy. Of those comments, 65 were identified as coming from respiratory therapists and 18 were identified from other clinicians, including pulmonologists. Comments were also received from representatives of American Thoracic Society, American Academy of Sleep Medicine, CHEST and the Optimal Noninvasive Ventilation Medicare Access Promotion Technical Expert Panel (TEP). Some of these clinicians identified themselves as actively treating their patients with the respiratory devices in question. These comments were read and considered carefully, and they formed the basis of many of the changes made to the policy.

Finally, CMS met several times with representatives of both the related medical and home care fields, who provided education about their real-world experience with noninvasive ventilation therapy.

We have found that the well-rounded expertise and viewpoints provided by the above stakeholders has been invaluable in the preparation of this policy.

Comment: Some commenters asserted that the NCD will limit the autonomy of providers to prescribe the respiratory equipment they believe is best for their patients.

Response: We disagree. The requestors of this NCD, the Optimal Noninvasive Ventilation Medicare Access Promotion Technical Expert Panel (TEP), noted barriers to the use of NIV best practices in the care of COPD patients. Specifically, CMS was asked by the requestors of this NCD to establish Medicare coverage for RADs with back up rate features in an accelerated manner compared to the MAC-level policies set forth in LCD 33800. CMS was also requested to provide criteria that would support coverage of initiating NIV with an HMV.

These new coverage criteria in this NCD were provided with the knowledge that over the past years, the capabilities of home mechanical ventilators and bi-level respiratory assist devices have advanced, and in some cases, have blurred. This has resulted in confusion among providers regarding the distinctions that define the covered uses of different items of respiratory equipment, such as RADs and HMVs, as allowed by statute and Medicare policy. Therefore, they have asked CMS to issue an NCD to establish national coverage and clarify the relevant coverage criteria of the appropriate equipment for their patients, at the time it is needed.

The final NCD establishes expanded national coverage so the most appropriate NIV can be provided to Medicare patients with COPD. In addition to national coverage, MACs have the discretion to cover reasonable and necessary NIV including HMVs, beyond the NCD.

Comment: A few commenters have requested that Medicare policies concerning respiratory diseases other than COPD be updated.

Response: Medicare policies concerning respiratory diseases for other indications than COPD are beyond the scope of this NCD. To request an NCD on another topic, please see <https://www.cms.gov/medicare/coverage/determination-process/request> and the related downloads.

The LCD Reconsideration Process (the modification of an existing final policy), is outlined in chapter 13 of the Program Integrity Manual at <https://www.cms.gov/medicare/regulations-guidance/manuals/internet-only-manuals-ioms>. To submit an LCD reconsideration, the inquirer should go to each individual MAC's website to find the link that denotes where to submit their reconsideration. Further information about the DME LCD reconsideration process can be found at: <https://med.noridianmedicare.com/web/jddme/policies/lcd/reconsideration> or <https://www.cgsmedicare.com/jc/coverage/reconsideration.html>.

The LCD Request Process is a mechanism by which interested parties within a contractor's jurisdiction may request a new LCD. This process has different procedures from an LCD Reconsideration Request and can be found at <https://med.noridianmedicare.com/web/jddme/policies/lcd/lcd-development> or

https://www.cmsmedicare.com/jc/coverage/lcd_request_process.html

Comment: Some commenters requested a delay in implementation date of this policy.

Response: As set forth in the Revised Process for Making National Coverage Determinations Federal Register notice issued on August 7, 2013, the effective date for an NCD is the same date as the publication date of the final decision memorandum. See 78 FR 48169.

Comment: A commenter noted that claims for HMV devices used in AVAPS-AE or iVAPS-AE modes of therapy are currently being denied, citing the classification of these modes instead under E0471 (HCPCS code denoting respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)).

Response: The applicable payment methodology for HMVs and RADs is beyond the scope of this NCD.

Comment: A few commenters expressed concerns regarding the billing and payment for respiratory devices and supplies.

Response: Reimbursement of devices and supplies are beyond the scope of this NCD.

Comment: A few commenters strongly encouraged Medicare to cover the services of respiratory therapists (RTs).

Response: The Medicare related policies regarding RTs are beyond the scope of this NCD.

Comment: Commenters stated that they are not aware of any RADs without backup rate features currently available in the U.S. that have an FDA-approved indication for use aside from obstructive sleep apnea (OSA). In particular, these devices are not approved for respiratory insufficiency.

Response: The FDA does not regulate the practice of medicine. The specific device that is best for a patient's treatment is decided by the patient and their physician.

IX. CMS Analysis

NCDs are determinations by the Secretary with respect to whether or not a particular item or service is covered nationally by Medicare (§1869(f)(1)(B) of the Act). In order to be covered by Medicare, an item or service must fall within one or more benefit categories contained within Part A or Part B and must not be otherwise excluded from coverage. Moreover, with limited exceptions, the expenses incurred for items or services must be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member (§1862(a)(1)(A) of the Act).

When making NCDs, we evaluate the evidence related to our analytic questions based on the quality, strength and totality of evidence presented in the reviewed literature. As part of this evaluation, it is important to consider whether the evidence is relevant to the Medicare beneficiary population. In determining the generalizability of the results of the body of evidence to the Medicare population, we consider, at minimum, the age, race, and gender of the study participants.

This section provides an analysis of the evidence we considered during our review. The evidence includes the pertinent published medical literature and guidelines pertaining to the use of NIV for patients with chronic hypercapnic respiratory failure consequent to COPD. For details of each of the clinical trials, see the Evidence Table in Section VII above.

In this analysis, we addressed the question(s) below:

1. In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to provide coverage of a RAD with backup rate feature for initial NIV support in the home in the patient who either exhibits stable COPD or is status post a recent exacerbation of COPD?
2. In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to determine if there are any conditions under which coverage of an HMV is reasonable and necessary?
3. In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to establish a 180-day trial period to determine if the use of home NIPPV delivered either from a bi-level respiratory assist device or an HMV, is reasonable and necessary?

In evaluating the evidence that pertains to our key questions, we are placing high importance on the impact of the patient centered outcomes of mortality and the need for repeat hospitalizations in our beneficiary population that experiences COPD. We believe strongly that therapeutic interventions should better these characteristics of the disease while at the same time improving, or at least not worsening, the impact of the disease on the patient's perceived quality of life.

- 1. In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to provide coverage of a RAD with backup rate feature for initial NIV support in the home in the patient who either exhibits stable COPD or is status post a recent exacerbation of COPD?**

NIV has been validated as a useful treatment of hospitalized patients with acute hypercapnic respiratory failure consequent to COPD. In the inpatient environment, the treatment of acute hypercapnic respiratory failure with NIV is known to decrease length of stay, as well as reduce mortality and the risk of intubation (Gantzorn, Prior & Hilberg, 2019; Raveling et al., 2021). However, the evidence describing the benefit of home NIV in patients with chronic hypercapnia secondary to COPD has not been as well established (Suh, Murphy & Hart, 2019; Macrea & Coleman, 2022).

That long term home administration of NIV has not been considered a standard of care may be due to heterogeneity of the very studies performed to examine the treatment. For example, in a recent Cochrane review (Raveling et al., 2021), trials of individuals with stable COPD spanning from 1991 to 2019, included investigations of NIV (bi-level pressure support) applied with backup rates, without backup rates, with unspecified backup rates or with an unspecified ventilation mode. In another grouping of studies, the comparators of chronic NIV treatment in COPD patients were standard treatment or sham treatment in the form of CPAP, with NIV being applied in some investigations in addition to pulmonary rehabilitation or an exercise training program with

the control population receiving only the physical therapeutic program. We believe that a collection of studies with such fundamental and varied differences in management techniques may possess too many variables to determine the usefulness (or not) of home NIV in patients with severe COPD.

Nevertheless, in a previous Cochrane review which investigated the chronic use of NIV in patients with stable COPD, it was noted that while the therapeutic use of this treatment did not provide significant benefits in terms of gas exchange, exercise capacity, lung function or quality of life, there was a subgroup of COPD patients with severe hypercapnia who seemed likely to benefit from the treatment, especially when it was provided with high inspiratory pressures and when NIV was used for more than five hours per day (Raveling, et al., 2021).

The concern that low inspiratory pressures may not improve the blood gases or survival of patients with stable COPD had been previously considered by various investigators, including Windisch, Kostić, Dreher, Virchow & Sorichter (2005). These authors noted indirect evidence existed to support the hypothesis that more aggressive ventilation aimed at maximally decreasing PaCO₂ could provide beneficial effects for patients with stable hypercapnia due to COPD. Therefore, they performed a retrospective analysis of a medical database of stable COPD patients who presented with typical symptoms of hypercapnic respiratory failure (e.g. fatigue, dyspnea, morning headache) and who received pressure limited NPPV therapy in the assist/control mode by nasal mask in the hospital setting. NPPV was titrated to achieve passive ventilation with a maximal decrease in PaCO₂ by stepwise increases in inspiratory pressures. Supplemental oxygen was also added to the NPPV in order to maintain an arterial oxygen saturation greater than 95%. Patients were discharged from the hospital when a maximum reduction in PaCO₂ was achieved and maintained for two days with inspiratory pressures set to the maximum tolerated by each individual. Patients predominantly used their NPPV at night but could use it up to four hours during the daytime as needed to control hypercapnia and symptoms.

The authors found that NPPV used in the assist /controlled mode [3], along with supplemental O₂ using a high mean inspiratory pressure of 27.7 ± 5.9 cm H₂O (range 17- 40 cm H₂O) could be well tolerated over long periods of time by patients with stable hypercapnic COPD (mean age 63.4±9.7 years) at a mean respiratory rate of 20.8 ±2.5 breaths per minute (range 14-24 breaths per minute). Moreover, in the group of patients tested, daytime PaCO₂ during spontaneous breathing significantly decreased (6.9±8.0 mm Hg; 95% CI: -9.9 to -3.9) from 53.3±4.8 to 46.4 ± 7.0 mm Hg (p< 0.001) after 2 months. The 2-year survival rate was 86 %.

The ventilator parameters as exemplified above described more intense settings than did those of many studies that used lower levels of inspiratory positive airway pressures (IPAP) ranging from 12 to 18 cm H₂O. These higher settings were therefore designated high intensity NPPV and signaled the use of high inspiratory pressures with a high backup rate (slightly above the natural breathing frequency, typically 14-18 breaths per minute) targeted at producing significant reductions in PaCO₂ (Carlucci, Patout & Winck, 2023; Kaminska et al., 2021; Suh, Murphy & Hart, 2022; Windisch, Haenel, Storre & Dreher, 2009). Researchers believed that among the next steps for study of this topic was the verification through prospective randomized controlled trials that in individuals with chronic hypercapnic respiratory failure as a result of COPD, high intensity NPPV could improve clinical outcomes of lung function such as survival and reduction of exacerbation/hospitalization rates (Windisch et al., 2005; Windisch et al., 2009).

There are three trials meeting our inclusion criteria that address whether high intensity NPPV improves survival and/or reduces hospitalization of patients with hypercapnic COPD. (The fourth study noted in the Tables above (Clini, et al., 2002) did not provide high intensity NIV to its patient sample (Clini et al., 2002; Coleman, Wolfe & Kalhan, 2019) and therefore will not be discussed.) Though the details of these studies are summarized in Tables 1 and 2 above, for purposes of our analytic discussion, we highlight several aspects of these investigations emphasizing those points which allow us to associate the use of high intensity ventilation with a backup rate to our analytic questions and outcomes of interest for both patients experiencing stable COPD and those with recent exacerbations.

Kohnlein et al., 2014: In this trial, 195 patients with stable GOLD Stage IV COPD, PaCO₂ of 51.9 mm Hg or higher (mean PaCO₂ approximately 58 mm Hg) and a pH greater than 7.35, were randomized into two groups: those who were treated with standard therapy and those who were treated with standard therapy as well as NPPV targeted to reduce baseline PaCO₂ to either achieve a value lower than approximately 48 mmHg or to reduce the baseline value by 20% or more. As per the authors, these individuals had no acute exacerbation during the four week run in period before randomization, defined as an increase in or new onset of, more than one respiratory symptom (cough, sputum production, sputum purulence, wheezing, or dyspnea) lasting 2 days or more. The authors also required their patient population to have had no change of pharmacological treatment in the preceding four weeks. Potential patients were ineligible if they demonstrated a BMI ≥ 35 kg/m². Both groups were admitted to the hospital for initiation of treatment and for regularly scheduled follow up after randomization. All ventilators were set in pressure support mode; ventilation with high backup rates was preferred to achieve controlled ventilation, but assisted ventilation was also allowed if patients did not accept high backup rates. The mean inspiratory pressure was 21.6 (4.7) cm H₂O, the mean expiratory pressure was 4.8(1.6) cm H₂O and the mean backup rate was 16.1 (3.6) breaths per minute (range 2-24), reflective of a high intensity strategy. Mean NPPV use was 5.9 (3.1) hours per day. Long term oxygen therapy was allowed.

The primary outcome of this study was one-year all-cause mortality. The trial demonstrated a significant decrease in mortality when NPPV was added to usual treatment. NPPV treatment was associated with a one-year mortality of 12% (12/102 patients) in the intervention group as compared with 33% (31/93 patients) in the group who did not receive this treatment. There was also an effect on PaCO₂, as at the end of one year, the mean value in the intervention group was (approximately) 48.75 mm Hg versus (approximately) 55.50 mmHg in the control group. Changes in the disease specific quality of life summary scores of both the St George's Respiratory Questionnaire (SGRQ) and the Severe Respiratory Insufficiency Questionnaire (SRI) improved in favor of the NPPV group.

(We do note that the trial by Kohnlein and colleagues (2014) was terminated prior to attaining the full sample population. However, this was done as a result both of a change in national guidelines for the provision of NIV as well as the unexpectedly high mortality rate of the control group [Suh, Murphy & Hart, 2022]).

Struik et al., 2014: In the RESCUE study (Struik et al., 2014), 201 individuals treated as inpatients for acute hypercapnic respiratory failure secondary to COPD (GOLD stage 3 and 4), with ventilatory support (invasive or non-invasive) who exhibited prolonged hypercapnia (> 45 mm Hg for greater than 48 hours after termination of ventilatory support) were randomized to nocturnal NIV (bi-level spontaneous/timed mode; n=101) or standard treatment (n=100). Mean baseline PaCO₂ value was approximately 58.5 mm Hg for all patients. Patients randomized for NIV were discharged from the hospital with a mean IPAP of 19.2 ±3.4 and EPAP of 4.8 ±1.0 cm H₂O and a mean respiratory rate of 15 ±3 breaths/minute. Sixty-eight per cent of ventilated patients received nighttime oxygen. After one year, those who remained in the study in the intervention group (54/101), were ventilated with a mean IPAP of 21.0 ±3.4 and

an EPAP of 5.2 ± 1.2 cm H₂O. Mean duration of NIV use per night until last follow up or death was 6.3 ± 2.4 hours per night in the total group and 6.9 ± 2.1 hours per night in the completers. At one year, despite an improvement in day and night time PaCO₂, there was no improvement in time to readmission for respiratory causes or death (primary endpoint) in those who received nocturnal NIV versus those who did not.

Murphy et al., 2017: The Home Mechanical Ventilation versus Home Oxygen Therapy in COPD study (HOT-HMV) included individuals who had been hospitalized with an acute decompensated exacerbation of COPD requiring NIV and were screened for eligibility at least 2 weeks after resolution of decompensated acidosis and within 4 weeks of attaining clinical stability. Among other criteria, the patients were required to have persistent hypercapnia with PaCO₂ > 53 mmHg, pH greater than 7.3 breathing room air, hypoxemia, FEV1 < 50% predicted and FEV1/FVC < 60%. Exclusion criteria included a body mass index > 35 kg/m² or clinically significant obstructive sleep apnea syndrome.

Fifty-nine patients were randomized to home oxygen alone and 57 patients to home oxygen and bi-level positive airway pressure. The median ventilator settings at hospital discharge were an IPAP of 24 cm H₂O (IQR 22-26 cm H₂O), EPAP of 4 cm H₂O (IQR 4-5 cm H₂O), and a backup rate of 14 breaths per minute (IQR 14-16 breaths/minute). Ventilator use at 6 weeks was 4.7 hours per night (IQR, 2.5-5.6 hours per night), which increased during the trial to 7.6 hours per night (IQR, 3.6-8.4 hours per night) at 12 months. Home oxygen therapy was provided as needed in order to increase the PaO₂ level to greater than 60 mm Hg without producing decompensated respiratory failure.

The primary outcome was time to readmission or death within 12 months after randomization. Sixty-four patients (28 in the home oxygen therapy alone group and 36 in the home oxygen therapy plus home NIV group) completed the 12-month study period. There was a statistically significant between-group difference in daytime PaCO₂ at 6 weeks and 3 months favoring the home oxygen therapy plus home noninvasive ventilation group, but not at 12 months. Median time to hospital readmission or death was 4.3 months (IQR, 1.3-13.8 months) in the NIV group versus 1.4 months (IQR, 0.5-3.9 months) in the home oxygen group alone.; The 12-month risk of readmission was 63.4% in the NIV group versus 80.4% in the home oxygen group, yielding an absolute risk reduction of 17% (95% CI: 0.1%-34.0%). Twelve-month mortality was not significantly different between groups, but there was a reduction in the COPD exacerbation rate in the NIV group (median 3.8 exacerbations per year; IQR, 1.7-6.0) compared with home oxygen alone (median 5.1 exacerbations per year; IQR 1.0-9.2). There were also no significant differences in health-related quality of life as measured by the St. George's Respiratory Questionnaire or the Severe Respiratory Insufficiency Questionnaire mean scores at 12 months.

The studies performed by Kohnlein et al., 2014, Struik et al., 2014 and Murphy et al., 2017 noted above, utilized high inspiratory pressures and backup rates of respiration and are therefore classified as providing high intensity NIV. In the studies by Kohnlein et al., 2014 and Murphy et al., 2017, the application of home NIV led to improved survival or readmission rates. In contrast, though the RESCUE study by Struik et al., 2014, provided NIV at similar pressures and respiratory rates as in Kohnlein et al, 2014, it did not demonstrate improvement in mortality or readmission in patients with severe COPD who used NIV at home. The benefits found in the Kohnlein et al., 2014 and Murphy et al., 2017 studies contrasting with the lack of same in the RESCUE trial indicate that the timing of long-term high intensity NIV application may be crucial to its success. For those who are status post an acute exacerbation of disease, it appears to be prudent to reassess need for home high intensity NIV two to four weeks after resolution of the illness in order to show benefit of NIV compared with controls. More generally, it seems that that NIV may be best applied in the patient with persistent hypercapnia, as opposed to the individual who may still be recovering from an acute exacerbation (Coleman, Wolfe and Kalhan, 2019).

It is also important to note that in the Kohnlein et al., 2014 study, the St. George Respiratory Questionnaire summary scale score as well as the Severe Respiratory Insufficiency Questionnaire summary scale score improved more with NIV than with LTOT alone. In the Murphy et al., 2017 study at the end of 12 months, there were no significant differences demonstrated in the Severe Respiratory Insufficiency Questionnaire or the St. George's Respiratory Questionnaire. These findings provide evidence that appropriately applied high IPAP and high respiratory rates can improve outcomes in the patient with chronic COPD, without jeopardizing quality of life and adding to the patient's burden of disease.

Admittedly, this collection of literature has some limitations that are worthy of mention. Firstly, the Kohnlein et al., 2014 and Murphy et al., 2017 studies were conducted in Europe, and their protocols called for either hospital admissions every 3 months to ensure optimized medical and NIPPV treatment or NIV training from skilled teams at home ventilation centers in the United Kingdom. These conditions appear unique to European countries and are likely not generalizable to the US Medicare population. It is certainly possible that the extra services afforded to patients undergoing NIV in countries outside the US may have influenced the results of these investigations.

Important to the consideration of this NCA, we are also aware that there is some controversy as to whether or not the backup rates that accompany the high-intensity noninvasive ventilation approach play an important role in the management of hypercapnic respiratory failure in COPD patients or if it is only the high-pressure settings that are needed for the therapeutic management of the condition. We agree with the opinions expressed in national guidelines that the available studies on this topic are insufficient to recommend the use of high-pressure NIV as opposed to high intensity NIV, encouraging further research on the topic (Kaminska et al., 2021; Ergun et al., 2019).

There is also some concern that high intensity NIV as compared to low intensity NIV may cause a reduced cardiac output, particularly in those individuals with pre-existing severe cardiovascular disease. Data is also conflicting in this area and varying effects on cardiac output may depend on individual patient characteristics and device settings (Lukácsovits, Carlucci, Hill et al., 2012; Duiverman, Maagh, Magnet et al., 2017). Though this does not appear to cause a blanket reason to withhold high intensity NIV from appropriate patients with COPD, it does inform treating practitioners regarding potential adverse effects of the use of this therapy in patients with co-morbid heart conditions and the need to follow the heart function of these patients carefully (Duiverman et al., 2017).

Other potential adverse effects of NIV cited in the literature are dry throat, facial pain, fragmented sleep, impaired nasal breathing, abdominal bloating, flatulence, eye irritation, sleep impairment, nose bleeds, nausea, vomiting and facial pressure wounds (Windisch, Geiseler, Simon, Waltersbacher & Dreher, 2018). However, in the Kohnlein et al., 2014 study, the only side effect of the therapy reported was that of facial skin rashes which occurred in 14% of the intervention population (14 of 102 patients). This side effect was managed in all affected patients by changing the type of the mask worn. The Murphy et al., 2017 study did not report adverse events of NIV. The authors of the RESCUE trial stated they did not find a difference in adverse events between groups.

Another area of controversy in this field of long-term home NIV for COPD is the setting in which this therapy is initiated. Though some clinicians believe it best to admit their patients to hospitals or sleep laboratories to titrate NIV settings in order to initiate this therapy for their patients with chronic stable

COPD, the ATS suggested that an in-laboratory overnight PSG to titrate NIV in patients with chronic stable hypercapnic need not be used in those who are initiating NIV. However, there may be special circumstances in which in-laboratory overnight testing is warranted as described below (Macrea et al., 2020). Therefore, we believe it best to leave this decision to the discretion of the treating practitioner who will know the availability and quality of the local resources as well as the unique needs and potential complexities of the individual patient.

An important co-morbidity associated with COPD is obstructive sleep apnea (OSA), a disease characterized by repetitive closings of the upper airways during sleep (Marin, Soriano, Carrizo, Boldova & Celli, 2010). The prevalence of OSA in those with severe COPD (COPD-OSA overlap syndrome) is unknown (Macrea & Coleman, 2022), though moderate or severe sleep apnea has been generally diagnosed in 30–50% of COPD patients (Czerwaty, Dżaman, Sobczyk & Sikorska, 2023). This is an important consideration; the ATS has noted several studies demonstrating that those individuals with COPD and OSA have more profound nocturnal oxygen desaturations and sleep disturbances compared to individuals displaying either disease alone (Macrea et al., 2020). Moreover, with the co-existence of the two diseases, individuals may also have increased risk of hospitalization and death due to COPD exacerbation. (Kuklisova et al., 2017).

Neither the Murphy et al., 2017 nor the Kohnlein et al., 2014 study specifically examined how the overlap condition would affect the outcomes of NIV used for COPD. Currently practitioners may use CPAP or BPAP to treat their hypercapnic patients with overlap syndrome (Kuklisova et al., 2017, Nowalk, Neborak & Mokhesi, 2022; Orr et al. 2020; Suh, Murphy & Hart, 2022; Zheng et al., 2022), although for those with chronic respiratory failure titration with in-laboratory overnight testing may be useful to set EPAP parameters (Macrea et al., 2020; Macrea & Coleman, 2022). A concern of this approach though is that the high expiratory positive airway pressure (EPAP) that may be required to overcome upper airway obstruction in these individuals may lead to worsening lung hyperinflation which has been reported to be correlated with poor outcomes (Suh et al., 2022). We believe further study in this area is needed. In the meantime, whereas CPAP alone may be the therapeutic device of choice in those whose OSA is the major contributor to their chronic respiratory failure, we believe that those individuals with overlap syndrome whose hypercapnic state is judged to be mostly due to their COPD, may benefit from the use of bi-level respiratory assist devices.

Despite the questions still to be answered in this research field, overall, we find it difficult to ignore the significant outcomes in survival/mortality, hospital readmission rates and reduction in the exacerbation rate that have been achieved for COPD patients with severe disease using NIV at high inspiratory pressures with a high backup rate targeted at producing significant reductions in PaCO₂, as exhibited by the studies of Kohnlein et al., 2014 and Murphy et al., 2017. We also note that avoiding exacerbations and hospitalization due to exacerbations has been reported as the outcomes that patients with COPD consider to be the most important in this disease (Hurst, Skolnikb, Hansen et al., 2020).

Therefore, despite the limitations of the evidence, we will provide coverage of nocturnal bi-level respiratory assist devices with backup rate capability as initial therapy in the treatment of severe COPD. We believe that an essential criterion for initiation of a RAD with backup rate feature should be a daytime PaCO₂ measurement (≥ 52 mmHg by arterial blood gas), as was done in both the Kohnlein et al., 2014 and Murphy et al., 2017 studies. However, though improvement in PaCO₂ is a common endpoint used in studies of patients with chronic hypercapnic respiratory failure, it remains unclear if the benefit of PAP is mediated directly through PaCO₂ reduction or whether PaCO₂ is a marker for other PAP benefits such as ventilation/perfusion matching, respiratory muscle rest during sleep, improving airway obstruction, improvement in hypoxemia (Nowalk et al., 2022). Therefore, it is appropriate to characterize the successful use of bi-level respiratory assist devices with backup rate capability as achieving a normalization of PaCO₂, a 20% reduction in baseline PaCO₂, a stabilization of rising PaCO₂ and /or improved patient symptoms. Furthermore, the key to the potential success of this equipment are the patients selected for its use. Additionally, we cover bi-level respiratory assist devices with backup rate capacity for those individuals with chronic stable hypercapnic COPD or for those patients who have been hospitalized with an exacerbation of COPD and who remain hypercapnic for at least 2 weeks post discharge.

We do not, however, believe that high PaCO₂ levels must occur in the wake of low sleep oximetry values in order to obtain a RAD with backup for a patient with severe COPD. As reported in a poster presentation in 2016, six hospitalized GOLD stage 3 and 4 clinically stable individuals who used nasal oxygen (1–4 L), whose baseline resting PaCO₂ ≥ 52 mm Hg and who were nearing the end of a COPD exacerbation, were studied for 12 hours overnight off NIPPV. None of the recorded oximetry readings fell below 90% for any patient during the study period, yet median PvCO₂ values increased overnight by 6.65 ± 5.2 mmHg despite subjects spending 46% of the study time awake. Even though the study was small, it does illustrate that nocturnal venous hypercapnia in clinically stable COPD patients nearing the end of an exacerbation hospitalization can occur in the absence of significant hypoxemia (Kim, Marchetti & Criner; 2016).

More significantly perhaps, is that the literature has reported there are differences in the accuracy of the pulse oximeter readings when comparing the information obtained from these devices between persons who identified their race as Black or White. Though many of the individuals who identified themselves as Black did demonstrate accurate pulse oximeter values, their risk of experiencing occult hypoxemia (defined as an arterial oxygen saturation of $<88\%$ determined by arterial blood gas studies despite an oxygen saturation of 92 to 96% on pulse oximetry) was reported to be nearly three times that of individuals who designated themselves as White (Sjoding, 2020; CAG-00296R2, 2021). Such overestimation of oxygen saturation can foster inappropriate decision-making in the consideration of device needs for the COPD patient. Thus, we do not believe there should be a requirement for sleep oximetry testing in order to receive a RAD.

Additionally, given the uncertain nature of the optimum PAP devices/parameters that might be used for the treatment of COPD-OSA overlap syndrome, we believe that the choice between CPAP, low or high-intensity NIV to treat the combination of COPD and OSA depends on the individual characteristics of the patient's disease. Therefore, if sleep apnea is not the predominant cause of the hypercapnia in those individuals with overlap syndrome, it can be reasonable to consider treatment with NIV, depending on a patient's individual clinical characteristics.

2. In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to determine if there are any conditions under which coverage of an HMV is reasonable and necessary?

In developing this NCA for RADs with backup rate functionality, we acknowledge that there are constraints to this equipment that may limit its capabilities. As a result, there may be circumstances when NIV may be best delivered through an HMV to patients with COPD who manifest particular characteristics. To our knowledge, there is no literature that collectively addresses this topic in a rigorous manner; therefore, below we will describe several scenarios that the requestors of this NCA have highlighted for us.

As has been described in this NCA, bi-level respiratory assist devices for the treatment of hypercapnic COPD are not meant for continuous use. In the vast majority of cases, these devices are used only during the night with nasal or oronasal interfaces to allow for reduction of the symptoms and adverse events associated with hypercapnia. However, in some individuals, NIPPV use may extend into daytime hours. If this is the case, the use of facial masks during daylight hours impedes eating and drinking as well as social interaction. The prolonged use of these interfaces may also promote the formation of facial pressure sores (Pinto, 2017).

For those individuals who require the extended use of ventilatory support from nighttime into daylight hours to correct hypercapnia that persists despite optimized nocturnal NIV, mouthpiece ventilation (MPV) is an option to be considered. MPV is an on demand or intermittent type of ventilation where the patient initiates a device supported breath as s/he requires. It is not available on bi-level respiratory assist devices, but can be used with ventilators (Singh & Cao, 2020; Hansen-Flaschen & Ackrivo, 2023). In the home, MPV is usually performed via an HMV in the volume-assisted/controlled mode. Pressure modes are not usually utilized because of the high air flow that the devices continue to deliver when the patient is disconnected from circuit. Volume-cycled modes allow the patient to choose at every inspiration the amount of air which s/he wants to inhale, adjusting the seal with the lips on the mouthpiece (Pinto, 2017).

Though there are limitations to the use of MPVs, used with certain ventilators, inspiratory effort is not required to initiate this mode of breathing; instead, the patient can receive a breath through contact of the device tip with his/her lip, cheek or tongue or by placing their lips around the mouthpiece. In between breaths, appropriate device adjustments can reduce air flow to imperceptible rates. Users can take one breath every few minutes or continuously as desired. (Hansen-Flaschen & Ackrivo, 2023).

MPV has been reported to improve hypercapnia in patients with respiratory failure, in particular those with neuromuscular disease (Singh & Co, 2020). We could find no literature to describe the use of MPV in the home of the patient with hypercapnic COPD, though the interface has been used to treat COPD in hospitalized patients with acute exacerbations of COPD. In the inpatient setting, at least in the short term, symptoms or blood gases mostly improved (Glerant JC, Rose D, Oltean V et al., 2007; Nicolini A, Santo M, Ferrari-Bravo M & Barlascini, 2014; Annunziata, Lanza, Scotto Di Frega et al., 2018). Therefore, in the patient who requires daytime usage of respiratory assistance (in addition to nocturnal use), it may be reasonable and necessary to use MPV on an accommodating HMV.

For those individuals who require ventilatory support more than eight hours per 24 hour period, it may also be a pragmatic option to offer a nasal mask for use during daytime hours and a face mask (e.g. oronasal mask) for sleep. This may provide the patient with the ability to speak and eat while awake.

A differential feature between bi-level respiratory assist devices and ventilators is that the former have limited pressure capabilities; a characteristic that becomes important in the mechanism of patient ventilation. Provided the patient's respiratory muscles are relaxed, as they generally will be in long-term ventilator users utilizing controlled modes of NIV, the tidal volume achieved (the amount of air that is brought into and out of the lungs with every breath, a key determinant of the quantity of oxygen and carbon dioxide in the blood) will depend upon the difference between IPAP and EPAP (known as the pressure support). When ventilation during NIV is found to be inadequate, such as when there is persistent elevation of daytime PaCO₂, clinicians will frequently increase IPAP in order to augment tidal volume during each breath (Kinnear, Watson, Smith et al., 2017). The maximum IPAP that can be generated by a bi-level respiratory assist device is usually between 25-30 cm H₂O, while that of a traditional HMV may be much higher. (Hansen-Flaschen & Ackrivo, 2023). In some individuals, for example those who may be obese, it may not be possible to generate an IPAP large enough through the use of a bi-level respiratory assist device to sufficiently improve the patient's ventilatory status; consequently, an HMV may be reasonable and necessary.

When supplemental oxygen is required by an individual who is hypoxemic and using a bi-level device, special ports can be attached to the bi-level respiratory assist device in order to deliver oxygen to the patient. However, the fraction of inspired oxygen (FiO₂), the resultant concentration of oxygen in the gas mixture, is not able to be easily predicted in these circumstances. FiO₂ during NIV can be affected by many factors including the location of the port through which the oxygen is bled into the system, the pressure settings being used, the amount of oxygen flow that is being entrained in the system, the site of the leak port and the impact of the leaks that may be caused either by the mask-face interface and/or from the mouth itself if a nasal mask is used. Therefore, when precise oxygen delivery is required, it may be reasonable to use a ventilator that has the ability to accurately mix the gases together in order to get a predictable concentration of oxygen (Scala & Naldi, 2008; Schwartz, Kacmarek & Hess, 2004). Additionally, though no substantial evidence can be found to support a FiO₂ threshold, subject matter experts consulted by CMS have suggested that when severe hypoxemia is present defined by a supplemental oxygen requirement of greater than 4 liters per minute (FiO₂ 36%), it would be prudent that the amount of oxygen required be ensured through the use of an HMV.

As previously noted, HMs typically have additional monitoring, safety, alarm, and backup power features (batteries), not possessed by a RAD. As such, we believe this equipment may be beneficial for those patients with severe COPD for whom loss of ventilatory support would, within minutes to hours, cause a life-threatening condition (e.g. those individuals with comorbid neuromuscular disease or diaphragmatic paralysis).

Based on the above discussion, and that the external Technology Assessment did not find any studies that compared the initiation criteria among different ventilatory devices (HMV vs. BPAP vs. CPAP) we do not believe that there is sufficient information to provide a policy that would definitively describe the difference between all patients with CRF and hypercapnia who have need for an HMV rather than a RAD in all situations. However, there are specific medical situations that may influence the choice between these two devices. Based on the evidence above, we will cover an HMV when a beneficiary requires a FiO₂ ≥ 36%, or when ventilatory support is required beyond nocturnal hours to reduce hypercapnia (and a MPV or an additional mask may be needed) or when the consistent use of a RAD with back up rate feature is not likely to achieve the outcomes of improved PaCO₂ and/or symptoms. Due to the alarms and internal battery of an HMV, we will cover the use of this device, if the unrecognized loss of ventilatory support in the home could cause a threat to the life of a patient.

We believe there exist some situations, perhaps driven more by clinical experience than literature, where it is medically appropriate for a patient to have access to either a RAD or home mechanical ventilator (depending on the beneficiary's individualized needs) at the time of hospital discharge. Based on the definitions of treatment success and failure posed by Mosher et al. (2022), we consider it to be clinically appropriate for a hospitalized patient to use these devices at home immediately after hospital discharge if the individual has experienced an acute exacerbation of COPD and cannot be 'liberated' from respiratory support as an inpatient without the demonstrated threat of serious consequence in the short term, such as the worsening of hypercapnia, the

need for the use of invasive ventilatory assistance or death. Therefore, we will cover use of a RAD or an HMV when the beneficiary requires continuation of device usage to avoid rapidly developing signs and symptoms of severe chronic respiratory failure upon hospital discharge after the exacerbation of COPD.

In circumstances where a patient's need for an HMV, versus a RAD, is not defined in the NCD, the MAC has the discretion to cover NIV including HMVs, beyond the NCD, when reasonable and necessary.

3. In the patient with chronic hypercapnic respiratory failure consequent to COPD, is the evidence sufficient to establish a 180-day trial period to determine if the use of home NIPPV delivered either from a bi-level respiratory assist device or an HMV, is reasonable and necessary?

To our knowledge there are no RCTs that study the period of time needed to best allow COPD patients in need of NIV to adhere to the equipment and mode that their physician recommends in order to decrease PaCO₂ and/or related symptoms. However, in the Kohnlein et al., 2014 study, patients in the intervention group were admitted to the hospital for a mean of 5.6 ± 1.1 days in order to initiate their NIV therapy. In the intervention group, patients were advised to use NPPV for at least 6 h per day, preferably during sleep, but usage during daytime was also accepted. Over the course of the experimental year, at least one measure of exact ventilator usage was available in 122 3-months follow-up periods in a subset of 48 out of 102 patients (47%) of whom 65% (52.5% of periods) exceeded the prescribed usage time of more than 6 hours per day. Usage time was less than 3 hours in only 18.8% of patients (23.8% of periods). Mean NPPV usage was 5.9 ± 3.1 hours per day. In the one-year observation period, a total of nine patients discontinued NPPV. Three patients discontinued NPPV directly after initiation (after 1, 1, and 3 days). In the first 90 days a total of 4 patients discontinued NPPV; in the first 180 days a total of 5 patients discontinued NPPV (Kohnlein et al., 2014 and Supplementary appendix).

In the Murphy et al., 2017 trial, acclimatization to the use of high intensity NIV took 5-6 days (Coleman et al., 2019). By the end of 12 months, 5 patients had withdrawn (16 died). Ventilator use at 6 weeks for those who remained in the trial was 4.7 hours per night (IQR, 2.5-5.6 hours per night), which increased during the trial to 7.6 hours per night (IQR, 3.6-8.4 hours per night) at 12 months. (Murphy et al., 2017, Supplementary Online Content).

The evidence reviewed demonstrates that the COPD patients who participated in these European studies were introduced and acclimatized to their NIPPV in a matter of days. We understand that this occurred in highly supportive facility environments which are unlikely to be reproduced in the United States. Specifically, in the case of Medicare patients, though initiation of the device may take place in home or in facility depending on the judgement of the treating physician and the resources available, we expect the full adherence to the nightly use of NIPPV will most likely occur over a prolonged period of time while at home. Therefore, we believe it prudent to allow several months to accomplish this therapeutic task. We also note that the Kohnlein et al., 2014 and Murphy et al., 2017 (2017) studies as well as two evidence-based guidelines (Ergan et al., 2019; Kaminska et al., 2021) suggest that usage at least five hours per day will most likely provide the clinical benefits of delayed time to readmission or improvement of survival in those patients who utilize NIPPV.

At the time of the writing of this NCA, the evaluation of a Medicare beneficiary with COPD to continue the use of a RAD (with or without a backup rate feature) beyond three months is to occur no sooner than 61 days and no later than 90 days after initiating therapy. Failure of the beneficiary to consistently use the respiratory equipment for an average of 4 hours per 24-hour period by this time represents non-compliant utilization of the device and a rationale for the MAC to deny its continued coverage (LCD 33800).

Though we appreciate the historical nature of these policy requirements, we must recognize that they do not take into account the characteristics of high intensity NIV. As we have noted above, high intensity ventilation signals the use of high inspiratory pressures with a high backup rate targeted at producing significant reductions in PaCO₂. From the evidence presented, there is a reasonable likelihood of increased survival or avoidance of rehospitalization when the parameters of this technique are fulfilled regularly by the patient.

While some authors define high intensity ventilation to be characterized by IPAP values typically above 20 cm H₂O with backup respiratory rates typically 14-18 breaths per minute with the objective of reducing PaCO₂ (Kaminska et al., 2021), other experts do not. Public comments and the reviewed literature (Ergan et al., 2019; Macrea et al., 2020; Kaminska et al., 2021) indicate that different patients may require different approaches to this type of respiratory therapy. Therefore, for coverage under this NCD, we define high intensity therapy as an IPAP ≥ 15 cmH₂O and back up rate of at least 14 breaths per minute, as suggested by several commenters.

To obtain the required parameters of high intensity NIV, a longer period of time than three months may be needed to determine if continued coverage is warranted for this therapeutic process. The evidence reviewed noted that excessive pressures and high backup rates may affect tolerability of NIV (Kaminska et al., 2021). For example, we have mentioned the possibility of adverse cardiac effects of this technique. Though this does not appear to cause a blanket reason to withhold high intensity from appropriate patients with COPD, it informs treating practitioners of potential adverse effects of the use of this therapy in patients with co-morbid heart conditions and the need to follow the heart function of these patients carefully (Duiverman et al., 2017), perhaps utilizing a slower ramp up period or lower pressures than would be otherwise used in a higher intensity protocol.

We believe, particularly for those who can obtain and potentially benefit from higher IPAP values than the minimum noted above, that a longer period of time than three months may be needed to determine if continued coverage is warranted for this therapeutic process. Authors have studied the home initiation of high intensity NIV in stable hypercapnic COPD patients targeted at a goal of significant reduction of arterial carbon dioxide (Duiverman, Vonk, Bladder, van Melle, Nieuwenhuis et al., 2020). Besides concluding that the process, with the use of telemedicine, is non-inferior to in-hospital initiation, it was demonstrated that as home IPAP parameters were increased gradually over a period of six months, lower PaCO₂ values could be achieved. Based on this finding, in some individuals, the need to continue the use of a RAD with a backup rate feature for the purpose of delivering high intensity NIV may require a longer period of time than three months to demonstrate that continued coverage is warranted. Therefore, the coverage criteria state patients have a period of up to six months to determine if the patient can successfully tolerate this ventilatory support.

In order to encourage the success of NIV therapy in the home, we require the beneficiary to achieve minimum usage criteria. As has been summarized in the evidence and analysis, the Kohnlein et al., 2014 and Murphy et al., 2017 studies as well as two evidence-based guidelines (Ergan et al., 2019; Kaminska et al., 2021) suggest that NIV usage at least five hours per day most likely provides the clinical benefits of delayed time to readmission or improvement of survival in COPD patients. It is also recognized that though adherence to therapy is key to the efficacy of home NIV, lesser amounts of NIV usage than 5 hours per 24 hour period may provide clinical benefit to the COPD patient (Ergan et al., 2019).

Commenters have advised that patient compliance to a schedule of NIV with usage of at least 4 hours/24 hours, on at least 70% of nights during thirty (30) day periods is sufficient to obtain successful clinical outcomes. In order to assure that the NIV devices prescribed are and remain reasonable and necessary for the treatment of the hypercapnia that occurs consequent to COPD and not an undue burden on the quality of life of our beneficiaries, Medicare requires at least two evaluations in the first year after initiation of the device, to determine the periods of time the patients employ their devices and the effects of these efforts. We believe that both physical measurements and/or directed inquiries related to symptom improvement, are the most informative means to determine if this treatment therapy is clinically benefitting the patient.

We are also aware that patients' needs and/or conditions may change as the course of their disease continues. For example, it may be that a patient with chronic stable COPD who qualifies for a RAD with a backup rate feature, may decline the therapy or s/he may attempt to use the therapy for a period of time, perceive it to be unhelpful and reject its further use. Then, after another period of time, or perhaps after an exacerbation with/without hospitalization, the patient may be ready to opt for a new trial of the therapy. The previous refusal to either initiate or continue the NIPPV earlier, would not preclude its use during another trial period; instead, coverage would be at the discretion of the DME MACs.

Moreover, even though it has been demonstrated that adherence to bi-level NIV is better with high pressures than it is with low pressures (Kaminska, Adam & Orr, 2024), we are aware that there will be some individuals who may not desire to use, or be able to tolerate, the parameters of high intensity noninvasive ventilation with a RAD as described above, and that there may be those patients whose PCO₂ level and/or symptoms may respond at least in part, to ventilatory therapy with a RAD without backup rate features. In such circumstances, the coverage qualifications for the use of a RAD without backup rate feature should be no more restrictive than current coverage and be comparable as possible to that for a device with backup rate feature. Therefore, if the patient's clinician determines it is medically necessary to initiate a RAD without backup rate feature, the device is covered if the patient (1) exhibits persistent hypercapnia as demonstrated by PaCO₂ ≥ 52 by arterial blood gas during awake hours while breathing his/her prescribed FiO₂; and (2) sleep apnea is not the predominant cause of the hypercapnia.

Summary

CMS believes that RADs with a backup rate feature can improve the health outcomes of certain individuals with chronic respiratory failure consequent to COPD when used to deliver high intensity noninvasive ventilation. Therefore, we are expanding coverage of nocturnal bi-level RADs for the treatment of hypercapnia in chronic severe COPD, to allow initiation of RAD therapy with backup rate capability. We are also allowing patients with COPD provided a RAD with a backup rate feature used to deliver high intensity NIV, a period of up to six months to determine if the high pressures and the respiratory rates defining the technique can be tolerated so as to provide signs and symptoms of disease improvement.

If a person cannot tolerate high-intensity noninvasive ventilation with a RAD with backup rate feature, they may use a RAD without a backup rate feature, if appropriate. The criteria for this are similar to those for RADs with a backup rate feature. CMS is also providing the clinical criteria that describe the need of a home mechanical ventilator, rather than a RAD, for those individuals with severe COPD and hypercapnia.

In summary, this NCD provides national coverage for the home use of RADs and HMs when applied to the treatment of Medicare patients who experience CRF consequent to COPD. All other coverage of these devices for the treatment of this disease process is at the discretion of the MACs.

X. Conclusion

B. Nationally Covered Indications

I. Respiratory Assist Devices (RADs)

(a) Initial Coverage Criteria

(i) RAD with Backup Rate Feature

The Centers for Medicare & Medicaid Services (CMS) will cover in the home a RAD with backup rate feature to deliver high intensity noninvasive ventilation (NIV) as treatment for patients with chronic respiratory failure (CRF) consequent to chronic obstructive pulmonary disease (COPD). A RAD with backup rate feature is covered in the home for an initial 6-month period for patients with COPD when **all the following** criteria are met:

- The patient exhibits hypercapnia as demonstrated by PaCO₂ ≥ 52 mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO₂; **and**
- Sleep apnea is not the predominant cause of hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of hypercapnia.); **and**
- The patient demonstrates **one of the following** characteristics:
 - Stable COPD, without increase in or new onset of more than one respiratory symptom (cough, sputum production, sputum purulence, wheezing, or dyspnea) lasting 2 or more days and no change of pharmacological treatment during the 2-week period before initiation of NIV, **or**
 - Hypercapnia present for at least 2 weeks post hospitalization after resolution of an exacerbation of COPD requiring acute NIV.

By the end of the initial 6- month period, a RAD with backup rate feature must be utilized as high intensity therapy, defined as a minimum IPAP ≥ 15 cm H₂O and backup respiratory rate of at least 14 breaths per minute.

(ii) RAD without Backup Rate Feature

CMS will cover in the home a RAD without backup rate feature for a patient with CRF consequent to COPD who cannot tolerate high intensity NIV **or** for whom the backup rate feature is otherwise medically inappropriate. A RAD without backup rate feature is covered in the home for an initial 6-month period for patients with COPD when **all of the following** criteria are met:

- The patient exhibits hypercapnia as demonstrated by PaCO₂ ≥ 52 mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO₂; **and**
- Sleep apnea is not the predominant cause of the hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of the hypercapnia.).

(iii) RAD Upon Hospital Discharge

CMS will cover in the home a RAD with or without backup rate feature immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient required either a RAD or ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO₂ after discharge.

(b) Continuing Usage Criteria for a RAD

Patients must be evaluated at least twice within the first year after initially receiving a RAD. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.

First evaluation:

By 6 months after receiving initial coverage of a RAD, the treating clinician must establish that usage criteria and clinical outcomes are being met. Specifically, the patient must be determined by a clinician to use the RAD at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period and achieve **at least one** the following clinical outcomes:

- Normalization (< 46 mmHg) of PaCO₂, **or**
- Stabilization of a rising PaCO₂, **or**
- 20% reduction in PaCO₂ from baseline value, **or**
- Improvement of **at least one** of the following patient symptoms associated with chronic hypercapnia:
 - headache
 - fatigue
 - shortness of breath
 - confusion
 - sleep quality

Second evaluation:

Between 7-12 months after initially receiving a RAD, the treating clinician must establish the patient is using the device at least 4 hours per 24-hour period on at least 70% of days in each paid rental month.

Post second evaluation:

The patient must be using the device at least 4 hours per 24-hour period on at least 70% of days in each remaining paid rental month and any month in which accessories/supplies are dispensed.

II. Home Mechanical Ventilators**(a) Initial Coverage Criteria**

CMS will cover a home mechanical ventilator (HMV) used in a volume targeted mode as treatment for a patient with chronic respiratory failure (CRF) consequent to chronic obstructive pulmonary disease (COPD) who exhibits certain clinical characteristics.

*(i) An HMV is covered for an initial 6-month period for patients with COPD when **all of the following** criteria are met:*

- The patient exhibits hypercapnia as demonstrated by PaCO₂ ≥ 52 mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO₂; **and**
- Sleep apnea is not the predominant cause of the hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of the hypercapnia.); **and**
- The patient demonstrates **at least one** of the following characteristics:
 - Requires oxygen therapy at an FiO₂ ≥ 36% or ≥ 4L nasally, **or**
 - Requires ventilatory support for more than 8 hours per 24-hour period, **or**
 - Requires the alarms and internal battery of an HMV, because the patient is unable to effectively breathe on their own for more than a few hours and the unrecognized interruption of ventilatory support is likely to cause a life-threatening condition if the patient or caregiver cannot be otherwise alerted as determined by the treating clinician, **or**
 - Per the treating clinician, none of the below are likely to be achieved with consistent use of a RAD with backup rate feature for at least 4 hours per 24-hour period on at least 70% of days because the patient's needs exceed the capabilities of a RAD as justified by the patient's medical condition:
 - Normalization (< 46 mmHg) of PaCO₂, **or**
 - Stabilization of a rising PaCO₂, **or**
 - 20% reduction in PaCO₂ from baseline value, **or**
 - Improvement of **at least one** of the following patient symptoms associated with chronic hypercapnia:
 - headache
 - fatigue
 - shortness of breath
 - confusion
 - sleep quality

(ii) Home Mechanical Ventilator Use Upon Hospital Discharge

CMS will cover in the home an HMV used in a volume targeted mode immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient's needs exceeded the capabilities of a RAD (with or without backup rate feature) and required usage of a ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO₂ after discharge.

(b) Continuing Usage Criteria for an HMV

Patients must be evaluated at least twice within the first year after initially receiving an HMV. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.

First evaluation:

By 6 months after receiving initial coverage of an HMV, the treating clinician must establish that usage criteria are being met. The patient must be determined by a clinician to use the HMV at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period.

Second evaluation:

Between 7-12 months after initially receiving an HMV, the treating clinician must establish the patient is using the device at least 4 hours per 24-hour period on at least 70% of days in each paid rental month.

Post second evaluation:

The patient must be using the device at least 4 hours per 24-hour period on 70% of days in each paid rental month.

(c) Masks for HMVs

For patients who use an HMV in a volume targeted mode: 1) for greater than 8 hours in any 24-hour period; and 2) use an oronasal mask at night, a different interface (e.g., mouthpiece ventilation or nasal mask) is covered for daytime hours. Note, coverage of such supplies does not exclude coverage of additional supplies necessary for the effective use of the HMV.

C. Nationally Non-Covered Indications

N/A

D. Other

Medicare Administrative Contractors (MACs) may make reasonable and necessary determinations under section 1862(a)(1)(A) of the Social Security Act for any patient seeking initial coverage or continued coverage for RADs or HMVs used as treatment of chronic respiratory failure consequent to COPD.

See Appendix A for the manual language.

Additionally, we will make conforming changes in Section 280.1 (Durable Medical Equipment List) of the National Coverage Determinations (NCD) Manual to add a cross reference to the new NCD Section 240.9 (NIPPV in the Home for the Treatment of CRF Consequent to COPD).

APPENDIX A

Medicare National Coverage Determinations Manual

Draft

This draft NCD is subject to formal revisions and formatting changes prior to the release of the final NCD contractor instructions and publication in the Medicare National Coverage Determinations Manual.

Table of Contents

(Rev.)

240.9 - Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chronic Obstructive Pulmonary Disease (COPD)

A. General

Respiratory assist devices (RADs) with bi-level capability, with or without a backup rate feature, are devices that typically use a non-invasive interface (mask) to deliver a higher level of airway pressure when the patient inhales than when the patient exhales. A backup rate feature on certain RADs enables the device to provide a prespecified respiratory rate if the patient's spontaneous respiratory rate decreases below a set number.

Compared with RADs, home mechanical ventilators typically have additional ventilatory modes, monitoring, ventilator control, and safety, alarm, and backup power features (batteries).

B. Nationally Covered Indications

I. Respiratory Assist Devices (RADs)

(a) Initial Coverage Criteria

(i) RAD with Backup Rate Feature

The Centers for Medicare & Medicaid Services (CMS) will cover in the home a RAD with backup rate feature to deliver high intensity noninvasive ventilation (NIV) as treatment for patients with chronic respiratory failure (CRF) consequent to chronic obstructive pulmonary disease (COPD). A RAD with backup rate feature is covered in the home for an initial 6-month period for patients with COPD when ***all the following*** criteria are met:

- The patient exhibits hypercapnia as demonstrated by $\text{PaCO}_2 \geq 52$ mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO_2 ; ***and***
- Sleep apnea is not the predominant cause of hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of hypercapnia.); ***and***
- The patient demonstrates ***one of the following*** characteristics:

- Stable COPD, without increase in or new onset of more than one respiratory symptom (cough, sputum production, sputum purulence, wheezing, or dyspnea) lasting 2 or more days and no change of pharmacological treatment during the 2-week period before initiation of NIV, **or**
- Hypercapnia present for at least 2 weeks post hospitalization after resolution of an exacerbation of COPD requiring acute NIV.

By the end of the initial 6-month period, a RAD with backup rate feature must be utilized as high intensity therapy, defined as a minimum IPAP ≥ 15 cm H₂O and backup respiratory rate of at least 14 breaths per minute.

(ii) RAD without Backup Rate Feature

CMS will cover in the home a RAD without backup rate feature for a patient with CRF consequent to COPD who cannot tolerate high intensity NIV **or** for whom the backup rate feature is otherwise medically inappropriate. A RAD without backup rate feature is covered in the home for an initial 6-month period for patients with COPD when **all of the following** criteria are met:

- The patient exhibits hypercapnia as demonstrated by PaCO₂ ≥ 52 mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO₂; **and**
- Sleep apnea is not the predominant cause of the hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of the hypercapnia.).

(iii) RAD Upon Hospital Discharge

CMS will cover in the home a RAD with or without backup rate feature immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient required either a RAD or ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO₂ after discharge.

(b) Continuing Usage Criteria for a RAD

Patients must be evaluated at least twice within the first year after initially receiving a RAD. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.

First evaluation:

By 6 months after receiving initial coverage of a RAD, the treating clinician must establish that usage criteria and clinical outcomes are being met. Specifically, the patient must be determined by a clinician to use the RAD at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period and achieve **at least one** the following clinical outcomes:

- Normalization (< 46 mmHg) of PaCO₂, **or**
- Stabilization of a rising PaCO₂, **or**
- 20% reduction in PaCO₂ from baseline value, **or**
- Improvement of **at least one** of the following patient symptoms associated with chronic hypercapnia:
 - headache
 - fatigue
 - shortness of breath
 - confusion
 - sleep quality

Second evaluation:

Between 7-12 months after initially receiving a RAD, the treating clinician must establish the patient is using the device at least 4 hours per 24-hour period on at least 70% of days in each paid rental month.

Post second evaluation:

The patient must be using the device at least 4 hours per 24-hour period on at least 70% of days in each remaining paid rental month and any month in which accessories/supplies are dispensed.

II. Home Mechanical Ventilators

(a) Initial Coverage Criteria

CMS will cover a home mechanical ventilator (HMV) used in a volume targeted mode as treatment for a patient with chronic respiratory failure (CRF) consequent to chronic obstructive pulmonary disease (COPD) who exhibits certain clinical characteristics.

*(i) An HMV is covered for an initial 6-month period for patients with COPD when **all of the following** criteria are met:*

- The patient exhibits hypercapnia as demonstrated by PaCO₂ ≥ 52 mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO₂; **and**
- Sleep apnea is not the predominant cause of the hypercapnia (Formal sleep testing is not required if, per the treating clinician, the patient does not experience sleep apnea as the predominant cause of the hypercapnia.); **and**
- The patient demonstrates **at least one** of the following characteristics:
 - Requires oxygen therapy at an FiO₂ $\geq 36\%$ or ≥ 4 L nasally, **or**
 - Requires ventilatory support for more than 8 hours per 24-hour period, **or**
 - Requires the alarms and internal battery of an HMV, because the patient is unable to effectively breathe on their own for more than a few hours and the unrecognized interruption of ventilatory support is likely to cause a life-threatening condition if the patient or caregiver cannot be otherwise alerted as determined by the treating clinician, **or**
 - Per the treating clinician, none of the below are likely to be achieved with consistent use of a RAD with backup rate feature for at least 4 hours per 24-hour period on at least 70% of days because the patient's needs exceed the capabilities of a RAD as justified by the patient's medical condition:

- Normalization (< 46 mmHg) of PaCO₂, *or*
- Stabilization of a rising PaCO₂, *or*
- 20% reduction in PaCO₂ from baseline value, *or*
- Improvement of *at least one* of the following patient symptoms associated with chronic hypercapnia:
 - headache
 - fatigue
 - shortness of breath
 - confusion
 - sleep quality

(ii) *Home Mechanical Ventilator Use Upon Hospital Discharge*

CMS will cover in the home an HMV used in a volume targeted mode immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient's needs exceeded the capabilities of a RAD (with or without backup rate feature) and required usage of a ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO₂ after discharge.

(b) Continuing Usage Criteria for an HMV

Patients must be evaluated at least twice within the first year after initially receiving an HMV. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.

First evaluation:

By 6 months after receiving initial coverage of an HMV, the treating clinician must establish that usage criteria are being met. The patient must be determined by a clinician to use the HMV at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period.

Second evaluation:

Between 7-12 months after initially receiving an HMV, the treating clinician must establish the patient is using the device at least 4 hours per 24-hour period on at least 70% of days in each paid rental month.

Post second evaluation:

The patient must be using the device at least 4 hours per 24-hour period on 70% of days in each paid rental month.

(c) Masks for HMVs

For patients who use an HMV in a volume targeted mode: 1) for greater than 8 hours in any 24-hour period; and 2) use an oronasal mask at night, a different interface (e.g., mouthpiece ventilation or nasal mask) is covered for daytime hours. Note, coverage of such supplies does not exclude coverage of additional supplies necessary for the effective use of the HMV.

C. Nationally Non-Covered Indications

N/A

D. Other

Medicare Administrative Contractors (MACs) may make reasonable and necessary determinations under section 1862(a)(1)(A) of the Social Security Act for any patient seeking initial coverage or continued coverage for RADs or HMVs used as treatment of chronic respiratory failure consequent to COPD.

Additionally, we will make conforming changes in Section 280.1 (Durable Medical Equipment List) of the National Coverage Determinations (NCD) Manual to add a cross reference to the new NCD Section 240.9 (NIPPV in the Home for the Treatment of CRF Consequent to COPD).

(This NCD last reviewed June 2025.)

[1] The overall average score reflects the votes of all persons who sit on the MEDCAC Panel, including guest panelists with topic expertise.

[2] The current Medicare coverage requirements for RADs (with or without a backup feature) state that beneficiaries must be re-evaluated to establish the medical necessity of continued coverage of the device beyond the first three months. While the beneficiary may need to be evaluated at earlier intervals after RAD therapy is initiated, the re-evaluation upon which Medicare will base a decision to continue coverage beyond this time must occur no sooner than 61 days after initiating therapy by the treating practitioner. Medicare will not continue coverage for the fourth and succeeding months of therapy until this re-evaluation has been completed.

There must be documentation in the beneficiary's medical record about the progress of relevant symptoms and beneficiary usage of the device up to that time. Failure of the beneficiary to be consistently using the RAD device for an average of 4 hours per 24 hour period by the time of the re-evaluation (on or after 61 days after initiation of therapy) would represent non-compliant utilization for the intended purposes and expectations of benefit of this therapy. This would constitute reason for the MAC to deny continued coverage as not reasonable and necessary (LCD 33800 Respiratory Assist Devices).

[3] The assist/control mode allows for a patient to trigger a ventilator, but also allows for a backup respiratory rate to be set. If the patient's spontaneous frequency of breathing is lower than the pre-set backup rate, the patient will follow the settings of the ventilator (Rabec et al., 2011).

Bibliography

Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Am J Respir Crit Care Med*. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP. PMID: 36856433; PMCID: PMC10111975.

Ankjærgaard KL, Tønnesen P, Laursen LC, Hansen EF, Andreassen HF, Wilcke JT. Home Non Invasive Ventilation (NIV) treatment for COPD patients with a history of NIV-treated exacerbation; a randomized, controlled, multi-center study. *BMC Pulm Med*. 2016 Feb 12;16:32. doi: 10.1186/s12890-016-0184-6. PMID: 26867542; PMCID: PMC4751632.

Annunziata A, Lanza M, Scotto Di Frega G, et al. Mouthpiece ventilation in COPD: an option for not-compliant patients. *European Respiratory Journal* 52.suppl 62 (2018): PA2368. Web. 25 Mar. 2024.

Bhatt SP, Wells JM, Iyer AS, Kirkpatrick DP, Parekh TM, Leach LT, Anderson EM, Sanders JG, Nichols JK, Blackburn CC, Dransfield MT. Results of a Medicare Bundled Payments for Care Improvement Initiative for Chronic Obstructive Pulmonary Disease Readmissions. *Ann Am Thorac Soc*. 2017 May;14(5):643-648. doi: 10.1513/AnnalsATS.201610-775BC. PMID: 28005410; PMCID: PMC5802596.

CAG-00296R2, Home Use of Oxygen and Home Oxygen Use to Treat Cluster Headaches. Accessed 10/15/2024 at: <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=301>.

Carlucci A, Patout M, Winck JC. Does one size fit all? An update on chronic ventilatory support in different respiratory illnesses. *Breathe* 2023; 19: 230046 [DOI: 10.1183/20734735.0046-2023].

Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, Montes de Oca M, Papi A, Sin DD, Han MK, Agustí A. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. *Am J Respir Crit Care Med*. 2022 Dec 1;206(11):1317-1325. doi: 10.1164/rccm.202204-0671PP. PMID: 35914087; PMCID: PMC9746870.

Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 2019 Sep 26;381(13):1257-1266. doi: 10.1056/NEJMr1900500. PMID: 31553837.

Chatburn RL. Which ventilators and modes can be used to deliver noninvasive ventilation? *Respir Care*. 2009 Jan;54(1):85-101. PMID: 19111109.

Chronic Obstructive Pulmonary Disease Disparities in Medicare Fee-For-Service Beneficiaries. Data Snapshot, February 2022. Accessed 3/25/2024 at: <https://www.gov/files/document/datasnapshot-copd-2022.pdf>.

Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N; Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. *Eur Respir J*. 2002 Sep;20(3):529-38. doi: 10.1183/09031936.02.02162001. Erratum in: *Eur Respir J*. 2002 Dec;20(6):1617. PMID: 12358325.

CMS National Coverage Analysis Evidence Review Guidance Document. August 7, 2024. Accessed October 9, 2024 at: <https://www.cms.gov/files/document/cms-evidence-review2024pdf.pdf>.

Coleman JM 3rd, Wolfe LF, Kalhan R. Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc*. 2019 Sep;16(9):1091-1098. doi:10.1513/AnnalsATS.201810-657CME. PMID: 31185181.

Correct Coding and Coverage of Ventilators - Revised July 2020. Accessed 7/14/2023 at: <https://dmeptac.com/palmetto/PDACY2.nsf/DIDC/N9L9D6LL9U~Articles%20and%20Publications~Advisory%20Articles>.

Csoma B, Vulpi MR, Dragonieri S, Bentley A, Felton T, Lázár Z, Bikov A. Hypercapnia in COPD: Causes, Consequences, and Therapy. *J Clin Med*. 2022 Jun 2;11(11):3180. doi: 10.3390/jcm11113180. PMID: 35683563; PMCID: PMC9181664.

Czerwaty K, Dżaman K, Sobczyk KM, Sikorska KI. The Overlap Syndrome of Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease: A Systematic Review. *Biomedicines*. 2022 Dec 21;11(1):16. doi: 10.3390/biomedicines11010016. PMID: 36672523; PMCID: PMC9856172.

Daher A, Dreher M. Oxygen Therapy and Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease. *Clin Chest Med*. 2020 Sep;41(3):529-545. doi: 10.1016/j.ccm.2020.06.014. PMID: 32800204.

Dekerlegand, RL, Cahalin, LP, Perme, C. "Respiratory Failure" in *Physical Rehabilitation: Evidence-Based Examination, Evaluation, and Intervention*, eds: MH Cameron and LG Monroe.

Elsevier Inc. 2007(2nd ed.); pp. 689-717. Draft Reviewer Guide for Ventilators. Anesthesiology, Respiratory, and Defibrillator Devices Group (FAD), Division of Cardiovascular, Respiratory, and Neurological Devices. July, 1995. Accessed December 5, 2023 at: <https://www.richardsonproducts.com/fdavent.pdf>.

Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. *Thorax* 2010;65:303-308.

Duiverman ML, Maagh P, Magnet FS, Schmoor C, Arellano-Maric MP, Meissner A, Storre JH, Wijkstra PJ, Windisch W, Callegari J. Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study. *Respir Res*. 2017 May 2;18(1):76. doi: 10.1186/s12931-017-0542-9. PMID: 28464911; PMCID: PMC5414301.

Duiverman ML, Vonk JM, Bladder G, van Melle JP, Nieuwenhuis J, Hazenberg A, Kerstjens HAM, van Boven JFM, Wijkstra PJ. Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. *Thorax*. 2020 Mar;75(3):244-252. doi: 10.1136/thoraxjnl-2019-213303. Epub 2019 Sep 4. PMID: 31484786; PMCID: PMC7063397.

Ergan B, Oczkowski S, Rochweg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. *Eur Respir J*. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. PMID: 31467119.

Federal Register, Volume 71, No. 18, January 27, 2006; 4518- 4525. Accessed on 12/4/2023 at: <https://www.govinfo.gov/content/pkg/FR-2006-01-27/pdf/06-798.pdf>.

Federal Register, Volume 89, No. 121, June 24, 2024; 52474. Accessed on 09/24/2024 at: <https://www.govinfo.gov/content/pkg/FR-2024-06-24/pdf/FR-2024-06-24.pdf>.

Fortis S. Why Home Noninvasive Ventilation Should Begin in the Hospital, Not at Home. *Am J Respir Crit Care Med* 2024; 210:260-261.

Frazier, WD, DaVanzo JE, Dobson A, Heath S, Mati K. Early Initiation of non-invasive ventilation at home improves survival and reduces healthcare costs in COPD patients with chronic hypercapnic respiratory failure: A retrospective cohort study. *Respiratory Medicine*. 2022. <https://doi.org/10.1016/j.rmed.2022.106920>.

Frazier WD, Murphy R, van Eijndhoven E. Non-invasive ventilation at home improves survival and decreases healthcare utilization in medicare beneficiaries with Chronic Obstructive Pulmonary Disease with chronic respiratory failure. *Respir Med*. 2021 Feb;177:106291. doi: 10.1016/j.rmed.2020.106291. Epub 2020 Dec 30. PMID: 33421940.

Frazier W, van Eijndhoven E, Murphy R, Jena AB. Noninvasive ventilation at home reduces mortality in COPD with CRF. *Am J Manag Care*. 2021 Sep 1;27(9):e308-e315. doi: 10.37765/ajmc.2021.88743. PMID: 34533913.

Gantzhorn EK, Prior TS, Hilberg O. Long-term non-invasive ventilation for stable chronic hypercapnic COPD. *Eur Clin Respir J*. 2019 Jul 23;6(1):1644893. doi: 10.1080/20018525.2019.1644893. PMID: 31448069; PMCID: PMC6691917.

Gillen EM, Mercado N, Sunkari K. Medicare Enrollees with COPD Compared to the General Population. 2021. Avalere 1201 New York Avenue NW Suite 1000 Washington, DC 20005. Accessed 6/26/2023 at: <https://avalere.com/insights/medicare-enrollees-with-copd-compared-to-the-general-population>.

Glerant JC, Rose D, Oltean V, Dayen C, Mayeux I, Jounieaux V. Noninvasive ventilation using a mouthpiece in patients with chronic obstructive pulmonary disease and acute respiratory failure. *Respiration*. 2007;74:632-639.

Global Initiative for Chronic Obstructive Lung Disease 2025 Report. Accessed December 18, 2024 at: https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf.

Gernhold, L., Neurohr, C., Tsitouras, K. et al. Hypercapnia and lung function parameters in chronic obstructive pulmonary disease. *BMC Pulm Med* 24, 345 (2024). <https://doi.org/10.1186/s12890-024-03151-1>.

Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med*. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST. PMID: 31613151; PMCID: PMC6794117.

Gudivada SD, Rajasurya V, Spector AR. Qualifying Patients for Noninvasive Positive Pressure Ventilation Devices on Hospital Discharge. *Chest*. 2020 Dec;158(6):2524-2531. doi: 10.1016/j.chest.2020.08.014. Epub 2020 Aug 14. PMID: 32798519.

Halpin DMG in Clinical Features and Diagnosis of COPD, Sam M Janes (ed). *Encyclopedia of Respiratory Medicine* (Second Edition). Academic Press, 2022, 621-630.

Hansen-Flaschen J, Ackrivo J. Practical Guide to Management of Long-Term Noninvasive Ventilation for Adults With Chronic Neuromuscular Disease. *Respir Care*. 2023 Mar 15;respca.10349. doi: 10.4187/respca.10349. Epub ahead of print. PMID: 36922023.

Hatipoğlu U, Aboussouan LS. Chronic hypercapnic respiratory failure and non-invasive ventilation in people with chronic obstructive pulmonary disease. *BMJ MED* 2022;1:e000146. doi:10.1136/bmjmed-2022-000146.

Hatipoglu U, Dean J, Aboussouan LS. Timing of Noninvasive Ventilation Initiation for Chronic Hypercapnic Respiratory Failure of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2025; 211:518-519.

Hatipoglu U, Lewarski JS, Chatburn RL. Home Noninvasive Ventilation for COPD: The Trouble with the Mode. *Respir Care* 2023; 68:1479-1480.

Hill NS, Criner GJ, Branson RD, Celli BR, MacIntyre NR, Sergew A on behalf of the ONMAP Technical Expert Panel; ONMAP Technical Expert Panel. Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. *Chest*. 2021 Nov;160(5):e389-e397. doi: 10.1016/j.chest.2021.06.082. Epub 2021 Jul 30. PMID: 34339684; PMCID: PMC8628175.

Home Ventilator Guide. International Ventilator Users Network, an affiliate of Post-Polio Health International. 2017. Accessed 3/22/2024 at: https://www.ventnews.org/files/ugd/fef361_6598f59fb9cd4c05a3bf564e5727ac29.pdf.

Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, Varghese P. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. *Eur J Intern Med*. 2020 Mar;73:1-6. doi: 10.1016/j.ejim.2019.12.014. Epub 2020 Jan 16. PMID: 31954592.

Hyzy RC, McSparron JI. Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications. Up to Date. PE Parsons & G Finlay, eds. UptoDate. Accessed 7/6/2023 at: <https://www.uptodate.com/contents/noninvasive-ventilation-in-adults-with-acute-respiratory-failure-benefits-and-contraindications>.

ISO 80601-2-72:2023 Medical electrical equipment Part 2-72: Particular requirements for basic safety and essential performance of home healthcare environment ventilators for ventilator-dependent patients. June 2023; edition 2. Accessed 09/24/2024 at: <https://www.iso.org/standard/83464.html>.

ISO 80601-2-79:2024 Medical electrical equipment Part 2-79: Particular requirements for basic safety and essential performance of ventilatory support equipment for ventilatory. August 2024; edition 2. Accessed 09/24/2024 at: <https://www.iso.org/standard/83465.html>.

Janssens JP, Michel F, Schwarz EI, Prella M, Bloch K, Adler D, Brill AK, Geenens A, Karrer W, Ognà A, Ott S, Rüdiger J, Schoch OD, Soler M, Strobel W, Uldry C, Gex G; on behalf of the Special Interest Group on Ventilation and Oxygen Therapy of the Swiss Society of Pneumology. Long-Term Mechanical Ventilation: Recommendations of the Swiss Society of Pulmonology. *Respiration*. 2020 Dec 10;1-36. doi: 10.1159/000510086. Epub ahead of print. PMID: 33302274.

Kaminska M, Adam V, Orr JE. Home Noninvasive Ventilation in COPD. *Chest*. 2024 Jun;165(6):1372-1379. doi: 10.1016/j.chest.2024.01.030. Epub 2024 Jan 30. PMID: 38301744; PMCID: PMC1177097

Kaminska M, Rimmer KP, McKim DA, Nonoyama M, Giannouli E, Morrison DL, O'Connell C, Petrof BJ & Maltais F (2021) Long-term non-invasive ventilation in patients with chronic obstructive pulmonary disease (COPD): 2021 Canadian Thoracic Society Clinical Practice Guideline update, *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, 5:3, 160-183, DOI: 10.1080/24745332.2021.1911218.

Kelly BT & Selim BJ. Noninvasive bilevel positive airway pressure therapy. In: *Encyclopedia of Sleep and Circadian Rhythms*, ed: Clete Kushida. Elsevier BV. 2023: Volume 2, pp. 422-433.

Kelly CR, Higgins AR, Chandra S. Noninvasive Positive-Pressure Ventilation, *Videos in Clinical Medicine Summary Points*. *N Engl J Med* 2015;372:e30. DOI:10.1056/NEJMvcm1313336.

Kerl J, Höhn E, Köhler D, et al. Spontaneous-timed versus controlled noninvasive ventilation in chronic hypercapnia - a crossover trial. *Medical Devices: Evidence and Research*. 2019;12:173-181. doi:10.2147/MDER.S190841.

Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. *Eur Respir J*. 2018 Nov 15;52(5):1801261. doi: 10.1183/13993003.01261-2018. PMID: 30237306.

Kim C, Marchetti N, Criner GJ. Nocturnal Hypercapnia and Acidosis Despite Normoxemia in Patients Hospitalized for Exacerbation of Chronic Obstructive Pulmonary Disease (poster). *Am J Respir Crit Care Med* 193;2016:A5190.

Kinnear W, Watson L, Smith P, Johnson L, Burrows S, Colt J, Sovani M, Khanna A. Effect of expiratory positive airway pressure on tidal volume during non-invasive ventilation. *Chron Respir Dis*. 2017 May;14(2):105-109. doi: 10.1177/1479972316674392. Epub 2016 Dec 6. PMID: 27923982; PMCID: PMC5720219.

Köhnlein T, Windisch W, Köhler D, Drabik A, Geiseler J, Hartl S, Karg O, Laier-Groeneveld G, Nava S, Schönhofer B, Schucher B, Wegscheider K, Crieé CP, Welte T. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. *Lancet Respir Med*. 2014 Sep;2(9):698-705. doi: 10.1016/S2213-2600(14)70153-5. Epub 2014 Jul 24. PMID: 25066329.

Kuklisova Z, Tkacova R, Joppa P, Wouters E, Sastry M. Severity of nocturnal hypoxia and daytime hypercapnia predicts CPAP failure in patients with COPD and obstructive sleep apnea overlap syndrome. *Sleep Med*. 2017 Feb;30:139-145. doi: 10.1016/j.sleep.2016.02.012. Epub 2016 May 6. PMID: 28215237.

Leivo-Korpela S, Rantala HA, Piili RP, Lehtimäki L, Lehto JT. Palliation of Dyspnea With Mouthpiece Ventilation in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Feasibility Study. *J Palliat Med*. 2023 Sep;26(9):1261-1265. doi: 10.1089/jpm.2023.0039. Epub 2023 May 4. PMID: 37155710.

Local Coverage Determination (LCD) 33718, Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea. Accessed on 5/13/2025 at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33718>.

Local Coverage Determination (LCD) 33800, Respiratory Assist Devices. Accessed on 12/4/2023 at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33800&ver=26&KeyWord=respiratory+assis&KeyWordLookUp=Title&KeyWordSearchType=Exact&bc=CAAAAAAAAAAAAA>.

Lukácsovits J, Carlucci A, Hill N, Ceriana P, Pisani L, Schreiber A, Pierucci P, Losonczy G, Nava S. Physiological changes during low- and high-intensity noninvasive ventilation. *Eur Respir J*. 2012 Apr;39(4):869-75. doi: 10.1183/09031936.00056111. Epub 2011 Sep 1. PMID: 21885393.

Macrea M, Coleman JM 3rd. The Role of Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. *Med Clin North Am*. 2022 Nov;106(6):961-969. doi: 10.1016/j.mcna.2022.07.004. Epub 2022 Oct 3. PMID: 36280339.

Macrea M, Oczkowski S, Rochweg B, Branson RD, Celli B, Coleman JM 3rd, Hess DR, Knight SL, Ohar JA, Orr JE, Piper AJ, Punjabi NM, Rahangdale S, Wijkstra PJ, Yim-Yeh S, Drummond MB, Owens RL. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020 Aug 15;202(4):e74-e87. doi: 10.1164/rccm.202006-2382ST. PMID: 32795139; PMCID: PMC7427384.

Malla G, Bodduluri S, Sthanam V, Sharma G, Bhatt SP. Access to Pulmonary Rehabilitation among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc*. 2023 Apr;20(4):516-522. doi: 10.1513/AnnalsATS.202204-318OC. PMID: 36476450; PMCID: PMC10112415.

Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. *Am J Respir Crit Care Med*. 2010 Aug 1;182(3):325-31. doi: 10.1164/rccm.200912-1869OC. Epub 2010 Apr 8. PMID: 20378728.

Marwah V, Dhar R, Choudhary R, Elliot M. Domiciliary noninvasive ventilation for chronic respiratory diseases. *Med J Armed Forces India*. 2022 Oct;78(4):380-386. doi: 10.1016/j.mjafi.2022.09.006. Epub 2022 Sep 29. PMID: 36267521; PMCID: PMC9577344.

May AM, Patel SR, Yamauchi M, Verma TK, Weaver TE, Chai-Coetzer CL, Thornton JD, Ewart G, Showers T, Ayas NT, Parthasarathy S, Mehra R, Billings ME. Moving toward Equitable Care for Sleep Apnea in the United States: Positive Airway Pressure Adherence Thresholds: An Official American Thoracic Society Policy Statement. *Am J Respir Crit Care Med*. 2023 Feb 1;207(3):244-254. doi: 10.1164/rccm.202210-1846ST. PMID: 36722719; PMCID: PMC9896653.

McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. *Eur Respir Rev*. 2013 Sep 1;22(129):365-75. doi: 10.1183/09059180.00003213. PMID: 23997063; PMCID: PMC9487346.

Mora Carpio AL, Mora JI. Assist-Control Ventilation. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Accessed 12/12/2023 @ <https://www.ncbi.nlm.nih.gov/books/NBK441856/>.

Mosher CL, Weber JM, Adagarla BS, Neely ML, Palmer SM, MacIntyre NR. Timing of Treatment Outcomes and Risk Factors for Failure of BPAP in Patients Hospitalized for COPD Exacerbation. *Respir Care*. 2022 Dec;67(12):1517-1526. doi: 10.4187/respcare.10155. Epub 2022 Oct 4. PMID: 36195347; PMCID: PMC9994036.

Murphy PB, Brignall K, Moxham J, Polkey M, Davidson C, Hart Nicholas. High pressure versus high intensity noninvasive ventilation in stable hypercapnic chronic obstructive pulmonary disease: A randomized crossover trial. *Int J Chron Obstruct Pulmon Dis*. 2012;7:811-818.

Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, Dowson L, Duffy N, Gibson GJ, Hughes PD, Hurst JR, Lewis KE, Mukherjee R, Nickol A, Oscroft N, Patout M, Pepperell J, Smith I, Stradling JR, Wedzicha JA, Polkey MI, Elliott MW, Hart N. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. *JAMA*. 2017 Jun 6;317(21):2177-2186. doi: 10.1001/jama.2017.4451. PMID: 28528348; PMCID: PMC5710342.

National Coverage Analysis, CAG - 00052N, Noninvasive Positive Pressure RADs for COPD. Accessed on 12/4/2023 at: <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=56&ver=&viewAMA=Y&bc=AAAAAAAAFAAA&>

National Coverage Determination 280.1, DurableMedical Equipment Reference List. 280.1 Accessed on 12/4/2023 at: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=190&ncdver=3&=2C&NCDSect=280.1&bc=BEAAAAAAAAQAAAA%3D%3D>

Nicolini A, Santo M, Ferrari-Bravo M, Barlaschini C. Open-mouthpiece ventilation versus nasal mask ventilation in subjects with COPD exacerbation and mild to moderate acidosis: a randomized trial. *Respir Care*. 2014 Dec;59(12):1825-31. doi: 10.4187/respcare.03009. Epub 2014 Aug 19. PMID: 25140033.

Nowalk NC, Neborak JM, Mokhlesi B. Is bilevel PAP more effective than CPAP in treating hypercapnic obese patients with COPD and severe OSA? *J Clin Sleep Med*. 2022 Jan 1;18(1):5-7. doi: 10.5664/jcsm.9710. PMID: 34608857; PMCID: PMC8807897.

Orr JE. Home Noninvasive Ventilation for COPD. *Respir Care*. 2023 Jul;68(7):1013-1022. doi: 10.4187/respcare.10788. PMID: 37353331; PMCID: PMC10289625.

Orr JE, Azofra AS, Tobias LA. Management of Chronic Respiratory Failure in Chronic Obstructive Pulmonary Disease: High-Intensity and Low-Intensity Ventilation. *Sleep Med Clin*. 2020 Dec;15(4):497-509. doi: 10.1016/j.jsmc.2020.08.007. PMID: 33131660.

Owens RL, Derom E, Ambrosino N. Supplemental oxygen and noninvasive ventilation. *Eur Respir Rev* 2023; 32: 220159 [DOI: 10.1183/16000617.0159-2022].

Pahal P, Hashmi MF, Sharma S. Chronic Obstructive Pulmonary Disease Compensatory Measures. [Updated 2023 Feb 19]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing. Accessed on 7/31/2023 at: <https://www.ncbi.nlm.nih.gov/books/NBK525962/>.

Pavwoski P, Shelgikar AV. Treatment options for obstructive sleep apnea. *Neurol Clin Pract*. 2017 Feb;7(1):77-85. doi: 10.1212/CPJ.0000000000000320. PMID: 29849228; PMCID: PMC5964869.

Pierson DJ. History and epidemiology of noninvasive ventilation in the acute-care setting. *Respir Care*. 2009 Jan;54(1):40-52. PMID: 19111105.

Pinto T, Chatwin M, Banfi P, Winck JC, Nicolini A. Mouthpiece ventilation and complementary techniques in patients with neuromuscular disease: A brief clinical review and update. *Chron Respir Dis*. 2017 May;14(2):187-193. doi: 10.1177/1479972316674411. Epub 2017 Feb 24. PMID: 27932555; PMCID: PMC5720221.

Potchileev I, Doroshenko M, Mohammed AN. Positive Pressure Ventilation. [Updated 2023 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Accessed on 2/5/2024 at:

<https://www.ncbi.nlm.nih.gov/books/NBK560916/#:~:text=Positive%20pressure%20ventilation%20describes%20the,in%20a%20critically%20ill%20patient>

Rabec C, Rodenstein D, Leger P, et al. Ventilator modes and settings during non-invasive ventilation: effects on respiratory events and implications for their identification. *Thorax* 2011;66:170-178.

Raveling T, Vonk JM, Hill NS et al. Home noninvasive ventilation in severe COPD: in whom does it work and how? *ERJ Open Res* 2024; 10.

Raveling T, Vonk J, Struik FM, Goldstein R, Kerstjens HA, Wijkstra PJ, Duiverman ML. Chronic non-invasive ventilation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2021 Aug 9;8(8):CD002878. doi: 10.1002/14651858.CD002878.pub3. PMID: 34368950; PMCID: PMC8407093.

Roussos C, Macklem PT. The respiratory muscles. *N Engl J Med*. 1982 Sep 23;307(13):786-97. doi: 10.1056/NEJM198209233071304. PMID: 7050712.

Rowling SC, Fløjstrup M, Henriksen DP, Viberg B, Hallenberg C, Lindholt JS, Alberg-Fløjborg A, Nanayakkara PWB, Brabrand M. Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study. *ERJ Open Res*. 2022 Feb 28;8(1):00535-2021. doi: 10.1183/23120541.00535-2021. PMID: 35237684; PMCID:PMC8883174.

Scala R, Naldi M. Ventilators for noninvasive ventilation to treat acute respiratory failure. *Respir Care*. 2008 Aug;53(8):1054-80. PMID: 18655744.

Schwartz AR, Kacmarek RM, Hess DR. Factors affecting oxygen delivery with bi-level positive airway pressure. *Respir Care*. 2004 Mar;49(3):270-5. PMID: 14982647.

Singh G, Cao M. Noninvasive Ventilator Devices and Modes. *Sleep Med Clin*. 2020 Dec;15(4):545-555. doi: 10.1016/j.jsmc.2020.08.005. Epub 2020 Sep 26. PMID: 33131664.

Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial bias in pulse oximetry measurement. *N Engl J Med*. 2020; 383:2477-2478.

Struik FM, Lacasse Y, Goldstein R, Kerstjens HA, Wijkstra PJ. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2013, Issue 6. Art. No.: CD002878. DOI: 10.1002/14651858.CD002878.pub2.

Struik FM, Sprooten RT, Kerstjens HA, Bladder G, Zijnen M, Asin J, Cobben NA, Vonk JM, Wijkstra PJ. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. *Thorax*. 2014 Sep;69(9):826-34. doi: 10.1136/thoraxjnl-2014-205126. Epub 2014 Apr 29. PMID: 24781217.

Suh ES, Murphy PB, Hart N. Home mechanical ventilation for chronic obstructive pulmonary disease: What next after the HOT-HMV trial? *Respirology*. 2019 Aug;24(8):732-739. doi: 10.1111/resp.13484. Epub 2019 Feb 7. PMID: 30729638.

Suh ES, Murphy PB, Hart N. Non-Invasive Ventilation in Acute, Post-Acute and Stable COPD, Editor(s): Sam M Janes, *Encyclopedia of Respiratory Medicine* (Second Edition), Academic Press, 2022, 244-260, ISBN 9780081027240. Accessed 3/25/2024 at: <https://doi.org/10.1016/B978-0-08-102723-3.00136-0>.

Suri TM, Suri JC. A review of therapies for the overlap syndrome of obstructive sleep apnea and chronic obstructive pulmonary disease. *FASEB BioAdvances*. 2021; 3: 683-693. <https://doi.org/10.1096/fba.2021-00024>.

van der Leest S, Duiverman ML. High-intensity non-invasive ventilation in stable hypercapnic COPD: Evidence of efficacy and practical advice. *Respirology*. 2019 Apr;24(4):318-328. doi: 10.1111/resp.13450. Epub 2018 Nov 30. PMID: 30500099.

Vasquez MM, McClure LA, Sherrill DL, Patel SR, Krishnan J, Guerra S, Parthasarathy S. Positive Airway Pressure Therapies and Hospitalization in Chronic Obstructive Pulmonary Disease. *Am J Med*. 2017 Jul;130(7):809-818. doi: 10.1016/j.amjmed.2016.11.045. Epub 2017 Jan 13. PMID: 28089799; PMCID: PMC5474150.

Wilson ME, Dobler CC, Morrow AS, Beuschel B, Alsawas M, Benkhadra R, Seisa M, Mittal A, Sanchez M, Daraz L, Holets S, Murad MH, Wang Z. Association of Home Noninvasive Positive Pressure Ventilation With Clinical Outcomes in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. *JAMA*. 2020 Feb 4;323(5):455-465. doi: 10.1001/jama.2019.22343. PMID: 32016309; PMCID: PMC7042860.

Wilson M, Wang Z, Dobler C, Morrow A, Beuschel B, Alsawas M, Benkhadra R, Seisa M, Mittal A, Sanchez M, Daraz L, Holets S, Murad MH. Noninvasive Positive Pressure Ventilation in the Home. Project ID: PULT0717 (Prepared by the Mayo Clinic Evidence-Based Practice Center under Contract No. HHS290201500013L_HHS29032004T). Rockville, MD: Agency for Healthcare Research and Quality. March 2019. Accessed 6/28/2023 at: <https://www.ncbi.nlm.nih.gov/books/NBK576007/>.

Windisch W, Geiseler J, Simon K, Walterspacher S, Dreher M, on behalf of the Guideline Commission; German National Guideline for Treating Chronic Respiratory Failure with Invasive and Non-Invasive Ventilation: Revised Edition 2017 - Part 1. Respiration. 2018; 96 (1): 66-97. <https://doi.org/10.1159/000488001>.

Windisch W, Geiseler J, Simon K, Walterspacher S, Dreher M; on behalf of the Guideline Commission. German National Guideline for Treating Chronic Respiratory Failure with Invasive and Non-Invasive Ventilation - Revised Edition 2017: Part 2. Respiration. 2018;96(2):171-203. doi: 10.1159/000488667. Epub 2018 Jun 26. PMID: 29945156.

Windisch W, Haenel M, Storre JH, Dreher M. High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. *Int J Med Sci*. 2009;6(2):72-6. doi: 10.7150/ijms.6.72. Epub 2009 Feb 27. PMID: 19277252; PMCID: PMC2653788.

Windisch W, Kostić S, Dreher M, Virchow JC Jr, Sorichter S. Outcome of patients with stable COPD receiving controlled noninvasive positive pressure ventilation aimed at a maximal reduction of Pa(CO₂). *Chest*. 2005 Aug;128(2):657-62. doi: 10.1378/chest.128.2.657. PMID: 16100151.

Zheng Y, Yee BJ, Wong K, Grunstein R, Piper A. A pilot randomized trial comparing CPAP vs bilevel PAP spontaneous mode in the treatment of hypoventilation disorder in patients with obesity and obstructive airway disease. *J Clin Sleep Med*. 2022;18(1):99-107.